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Abstract 
The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA 
mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-
MeG), by O6-methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor response is also 
dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that  
have activity independent of MGMT, MMR and p53. This is achieved through a switch of mechanism 
so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify 
guanine-N7 sites on DNA. Mono- and bi-functional analogs are reported and a quantitative structure-
activity relationship (QSAR) study identified the p-tolyl-substituted bi-functional congener as 
optimized for potency, MGMT-independence and MMR-independence. NCI60 data show the tumor 
cell response is distinct from other imidazotetrazines and DNA-guanine-N7 active agents such as 
nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further 
development and their improved in vitro activity validates the principles on which they were designed. 
 
Introduction 
The imidazotetrazine prodrug temozolomide 1 (TMZ), a DNA methylating agent, in combination 
with radiotherapy, is now first line treatment for glioblastoma multiforme (GBM) in North America 
and Europe. However, intrinsic and acquired resistance significantly limits the ultimate efficacy of 
therapy. In particular, tumor re-growth up to two years following TMZ treatment is aggressive and 
resistant to further TMZ therapy.1-3 This paper reports new compounds of the TMZ class that have 
activity independent of the two principal constraints on the ability of a tumor to respond to TMZ 
therapy: MGMT activity which directly repairs TMZ GO6-methylation of DNA, and MMR which 
enables the tumor response to TMZ therapy.2 
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Scheme 1.  The mechanism of action of temozolomide 1. 
 
At neutral pH, TMZ is relatively unstable (t1/2 = 1.24 h, pH 7.4)4 and undergoes hydrolytic ring-
cleavage to the open chain triazene 5-(3-methyltriazen-1-yl)- imidazole-4-carboxamide (MTIC, t1/2 = 8 
min, pH 7.4),5 which then fragments to the highly reactive electrophile, methyldiazonium (t1/2 = 0.39 
sec, pH 7.4).6-8 Methyldiazonium reacts with nucleophilic groups on DNA, resulting in DNA 
methylation, Scheme 1. Approximately 70% of the methyl groups transferred to DNA appear at N7-
guanine, 10 % at N3-adenine, and 5 % at O6-guanine sites. The N-methylation products are readily 
repaired by the base-excision repair pathways so are not major contributors to chemosensitivity.9 In 
contrast, O6-MeG lesions are reversed by direct removal by the MGMT protein. The MGMT gene is 
silenced by promoter methylation in approximately 35% of GBM.1 In these tumors, persistent O6-MeG 
lesions form wobble base-pairs with thymidine during replication; O6-MeG=T pairings result in futile 
cycles of mismatch repair, leading to stalled replication forks, DNA double-strand breaks and 
ultimately cell death.1 Low levels of MMR expression (or mutations leading to non-functional MMR) 
lead to a tolerant phenotype that cannot respond to TMZ. Consistent with these mechanisms of O6-
MeG processing and repair, high-level expression of the MGMT protein is a major mechanism of 
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regulation of MGMT expression are important causes of acquired TMZ resistance in GBM.2 Herein we 
report the synthesis, pre-clinical activity in vitro and QSAR of new imidazotetrazines that have activity 
independent of MMR and MGMT. 
 
Compound Design  
The imidazotetrazine bicycle is a prodrug of alkyldiazonium ions which are liberated by pH-
dependent hydrolysis.6 Careful control of these reactive intermediates, in particular the suppression of 
competing side reactions, such as hydrolysis, elimination or re-arrangement,10-12 is essential in the 
design of effective new agents.13, 14 Furthermore, of the methyl groups transferred from TMZ to DNA, 
only a small fraction becomes the therapeutically-beneficial O6-MeG lesion: we sought to achieve 
therapeutic benefit though generation of N7-G-adducts, the major products of reaction of TMZ with 
DNA, thereby making more efficient use of the imidazotetrazine prodrug.  We have designed novel 
series of mono- (2a–i) and bi-functional (3a–f) imidazotetrazines in which a 3-(2-anilinoethyl) group 
was substituted for the 3-methyl group of TMZ. The new compounds are efficient precursors of 
aziridinium ions, 4, Scheme 2. This strategy provides for effective control of the reactivity of incipient 
diazonium ions using a neighboring group participation mechanism not available to TMZ.  Moreover, 
aziridinium ions are reactive intermediates of proven clinical utility, being closely related to those 
generated by nitrogen mustard drugs, and are established as working through N7-guanine adducts.15 An 
additional feature of the drug design is the aniline para-substituent “X” of derivatives 2 and 3 that can 
be optimized to fine-tune pharmacological activity. This group affects the electron density at the aniline 
nitrogen by resonance or inductive effects and thereby controls the basicity and nucleophilicity of this 
site: i.e. the propensity either to protonate or to form an aziridinium ion. In addition, the bi-functional 
molecules would be expected to generate DNA cross-links, that would not be processed by MMR or 
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MGMT and so avert those constraints on activity; previous studies have demonstrated that polar16 and 
bulky17 GO6 adducts cannot be processed by MGMT. 
 
Scheme 2. Aziridinium ion formation by imidazotetrazine 2b.15 
Synthesis  
 
Scheme 3.  
The new imidazotetrazines were prepared by variants of the established TMZ synthesis where a 
diazoimidazole 5 is reacted with an isocyanate 6 to yield the imidazotetrazine, Scheme 3.18 The target 






































R = CH3            TMZ 1
R = CH2CH2Cl  MTZ
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precursors 7 are inherently unstable compounds as they bear incompatible functional groups. In the two 
aniline series, the anilines were sufficiently deactivated to allow isolation of the isocyanates without 
recourse to protecting group strategies. The formation of the relatively fragile tetrazine ring was usually 
planned to be the last step in the synthesis. 
 
Scheme 4. Route to bis-imidazotetrazines 3. Reagents and conditions: (i) CuCl, AcOH, Δ, 76–98%; 
(ii) NH2NH2·xH2O, IPA, Δ, 64–99%; (iii) NaNO2, AcOH, H2O, CH2Cl2, 0 °C; (iv) PhMe, Δ, [>95%]; 
(v) DMSO, RT, 2 d, 6–60% (over two steps) 
 
To prepare the dimers 3a–f, Cu(I)-catalyzed Aza-Michael conjugate addition of methyl acrylate to 
the requisite aniline furnished the diesters 8 in good (60–98%) yields, Scheme 4. Conversion to 
isocyanates 9 was achieved through the intermediate hydrazides 10 and azides 11 followed by Curtius 
rearrangement. For the electron rich anilines (X=CH3, OMe), hydrazide formation had to be performed 
under very mildly acidic (0.17 M AcOH) conditions to avoid nitration of the aniline ring (10e → 11f → 
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3f). This is an attractive route as the bis-hydrazides are usually solids and easily purified while the 
Curtius rearrangement produces pure isocyanates directly, free from contaminating by-products.  
 
Scheme 5 Route to mono-imidazotetrazines 2. Reagents and conditions: (i) CuCl, AcOH, Δ, 58–97%; 
(ii) NH2NH2·xH2O / IPA, Δ, 44–98%; (iii) NaNO2, AcOH, H2O, CH2Cl2, 0 °C; (iv) PhMe, Δ, [>95%]; 
(v) DMSO, RT, 6–51% over two steps. 
 
The mono-imidazotetrazine analogs 2a–i were similarly prepared from N-methyl anilines, Scheme 5. 
In one example, the secondary aniline version 2g (R=H, X=Cl) was achieved using a BOC protection 
strategy that exploited the relative acid stability of the imidazotetrazine ring. Carefully controlled 
diazotization (12f → 13f → 14f) yielded BOC-protected isocyanatoethylaniline 15f; tetrazine ring 
closure followed by final treatment with TFA gave secondary aniline 2g. As a similar yield was 
obtained omitting the BOC group, the protection was shown to be redundant. The p-nitro derivative 2e 
was accessed from hydrazide 13a by simultaneous diazotization and nitration under more vigorous 
conditions (10 M HCl); the mixture of regioisomers was carried through to the final step where the p-
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Figure 1 . In vitro chemosensitivity (IC50 / µM) of new imidazotetrazine compounds against A2780 
(MMR+) and A2780-cp70 (MMR–) cell lines in the absence (MGMT+) and presence (MGMT–) of the 
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MGMT inactivator PaTrin2 (10 µM). All data are the mean of ≥3 determinations, error bars are the SD; 
t-test analysis is presented in Table S3. * IC50 >250 µM. MEL, melphalan; CP, cisplatin. 
 
Screening of all new compounds for chemosensitizing efficacy was undertaken following a protocol 
by Margisson et al that used the MGMT and MMR-proficient ovarian carcinoma cell line A2780, and 
its MMR-deficient derivative A2780-cp70, Figure 1.19 To assess dependence of cytotoxicity on MGMT 
function, each cell line was further treated with the MGMT inactivator PaTrin2.20 The data are 
presented graphically in Figure 1 and fully tabulated in Table S1. As expected, sensitivity to TMZ and 
mitozolomide (MTZ) was highly dependent on both lack of MGMT activity and presence of wild-type 
MMR capacity. For TMZ, the IC50 was >250 µM in both A2780 and A2780-Cp70 cell lines, compared 
with IC50 = 8.5 and 231 µM respectively for the same cell lines co-treated with PaTrin2. In contrast, the 
novel imidazotetrazines were significantly more potent, with IC50 values in the A2780 wild-type line 
ranging from 22–73 µM for the mono-functional (2a–i) and 1–15 µM for the bi-functional (3a–f) 
compounds. Dependence on MMR can be examined by comparing the shaded bars with the grey bars 
(i.e. MMR+/MMR– with MGMT inactivated in both cases). For temozolomide the IC50 was >27–fold 
lower in the MMR-proficient cell line. For the new bi-functional agents 3, this ratio was reduced to 5–
5.8-fold and for the mono-functional agents 2, 2.8–10-fold. The extent of MGMT-mediated resistance 
can be assessed by comparing the shaded and the black bars (i.e. MGMT–/MGMT+ with MMR 
competent in both cases). Here, temozolomide was >30-fold more potent when MGMT was inactivated 
whilst for the new agents, this ratio was 0.5–5-fold for the bi-functional and 1.1–2.9-fold for the mono-
functional agents. Importantly, in the absence of MMR, all compounds showed activity greater than 
temozolomide irrespective of the MGMT status of the cells (white bars and grey bars) showing that 
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MMR-dependent toxicity and MGMT-mediated resistance are now only minor determinants of the 
chemosensitizing effect. 
 
The similarity of response of examples 2d and 2g indicate that the N-methyl aniline is not essential to 
activity as the secondary and tertiary aniline compounds are equipotent (see Figure 1 and Table S1). 
Retention of the BOC group in analog 2f significantly reduced potency, presumably by impeding the 
aziridine/aziridinium formation step. Nitration in the aniline ring, whether as the sole or as an 
additional substituent, resulted in reduced potency. This is consistent with electron withdrawal reducing 
nucleophilicity of the aniline and hence the propensity for aziridinium ion formation, (for examples, 
compare the compound pairs 3e/3f, 2a/2e, and 2b/2h). 
 
To probe the structure-activity relationship and examine MGMT and MMR dependence in more 
detail, the results for dimeric compounds 3a-e were presented in Hammett plots, Figure 2. The 
Hammett constant σ-p is a structural parameter that measures the electron donating or withdrawing 
effect of the substituent “X” on the aniline ring. The plot of IC50 against σ-p is informative in several 
respects, Figure 2A. For each cell type, the graph shows a pair of lines, the dotted line being MGMT-
inactivated data (i.e. PaTrin 2 present); the difference between the solid and dotted lines shows the 
effect of MGMT on the cellular response. For most analogs this separation is of the same order as the 
error bars on the data, so in effect is zero. This is a clear demonstration that these new compounds have 
activity independent of MGMT function and is consistent with a mechanism of action independent of 
guanine-O6 alkylation (or involving a guanine-O6 adduct that cannot be repaired by MGMT). The 
separation between the two pairs of lines is the MMR effect which ranges from about 2–5-fold on the 
IC50, which is greatly reduced from the >27-fold effect measured for TMZ. 
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p-Methyl-substituted analog 3b lies on a minimum in the graph so is optimally potent, with a 
modestly electron-donating substituent on the aniline ring, Figure 2A. The data for all analogues except 
3e (X = OMe) lie on exponential curves (see the semi-log plot, Figure 2B). The anomalous data for 3e 
are likely due to enhancement of the basicity of the aniline nitrogen lone pair leading to appreciable 
protonation at the pH of the experiment, and thereby a reduced propensity to act as a nucleophile in the 
aziridinium ion-forming reaction. These data clearly demonstrate the direct effect of electron density at 
the aniline nitrogen in determining the in vitro activity of the compounds, so provide further evidence 
that the aziridinium ion mechanism occurs in cells. 
  






Figure 2. (A, upper panel) Hammett plot of the IC50 data for the dimers 3a–e, in each case the MGMT– 
data are shown in dotted lines; the substituents X are shown in circles. (B, lower panel) QSAR Semi-
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log plot of log IC50 vs. Hammett constant (σ-p) for the dimeric imidazotetrazines 3a–e. Regression 
lines were fitted omitting the data for OMe derivative 3e. 
NCI60 Panel Data  
Compounds 2d, and 3c-e were selected for full screening in the NCI 60 cell line panel. Mean graph 
data are presented in Figures S1–6 and are summarized in Table 1. These data show that the NCEs 
have pharmacological activity distinct from TMZ. TMZ is essentially inactive against the panel (GI50 > 
10-4 M for 57/60 cell lines, Figure S1). In contrast, the new agents exhibit strong patterns of 
discrimination over a 2–3-log range of GI50 (Table 1 and Figures S2–5); this is important as it shows 
that the new compounds possess a degree of selectivity and are not uniformly cytotoxic against cells 
grown in culture.  These data compare favorably with the logGI50 mean and range data for established 
agents CHB, MEL, CP, BCNU and CCNU; this shows there is good reason to suppose that the new 
compounds may have an acceptable therapeutic index and be no more systemically toxic in vivo than 
these other clinically useful agents. 
 
 Log GI50  
Mean (SD) 
Log GI50 range 
2d –4.69 (0.58) 2.05 
3c –5.11 (0.69) 2.81 
3d –5.07 (0.52) 1.72 
3e –4.83 (0.46) 1.80 
MEL –4.54 (0.55) 1.88 
CHB –4.21 (0.56) 1.64 
CP –5.40 (1.10) 2.38 
BCNU –4.12 (0.82) 1.86 
CCNU –4.53 (0.48) 2.22 
 
Table 1 Summary of NCI60 statistics for compounds 2d, 3c–e, and established prodrugs for 
comparison. 
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Particular sensitivity is evident in the leukemia, CNS and ovarian sub-panels.  In the CNS sub-panel, 
the pattern of activity is similar to MTZ and CP, with particular sensitivity in the glioblastoma lines 
SF295 and SNB75. In the ovarian sub panel, particular sensitivity is seen in the OVACR-3 and SK-
OV-3 lines.  Here, in contrast to the CNS activity, the new compounds show improvement over CP (see 
Figure S6) this is a particularly interesting result given the wide clinical use of CP against ovarian 
adenocarcinoma and the fact that TMZ lacks clinical activity against ovarian cancer.21 
 
COMPARE analysis of mean graph data can be valuable in discerning molecular mechanisms of 
action. The similarity in patterns of response is assessed by the Pearson rank correlation coefficient, P: 
values > 0.7 are considered highly significant, values 0.6–0.7 less so.22, 23 Matrix COMPARE was 
valuable in confirming the novelty of mechanism of action of the new agents. In this method of data 
handling, the new compounds were compared with standard agents selected for similarities of chemical 
structure or predicted mechanism of action. Agents selected were other imidazotetrazines (TMZ, 
MTZ), nitrogen mustard cross linkers (chlorambucil CHB, melphalan MEL), nitrosoureas (1,3-Bis(2-
chloroethyl)-1-nitrosourea BCNU, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea CCNU) and CP, 
Table 2. Correlations amongst the four new imidazotetrazine compounds examined were all strong 
(0.92 ≤ P ≥ 0.77) and, interestingly, there was no clear discrimination between the mono- and bi-
functional agents: for monofunctional 2d, 0.83 ≤ P ≥ 0.77 and in particular P = 0.79 with the equivalent 
p-Cl dimer 3d. Gratifyingly, the new compounds showed only moderate correlations (0.52 ≤ P ≥ 0.38) 
with the established imidazotetrazines TMZ and MTZ, so are distinct as new members of this 
compound class. The absence of correlation with MTZ is significant as this compound, exhibits a 
characteristic pattern of differential activity across the panel, unlike TMZ.  
 
 - 15 - 
The putative DNA lesion of the bifunctional agents 3 is a five-atom crosslink, related in structure to 
those formed by the nitrogen mustard prodrugs; however, no drugs of this class showed strong 
correlations 0.59 ≤ P ≥ 0.29. Notably, there was no similarity to the nitrosoureas which are also 
diazonium ion precursors, 0.45 ≤ P ≥ 0.05. The new compounds all showed strong correlations with 
dacarbazine (DTIC, highest dose = 1 µM).  This observation is not easy to interpret, as this prodrug 
requires hepatic oxidative demethylation in order to release its active electrophile, so it is somewhat 
surprising that DTIC scored so highly against the new imidazotetrazines. Part of the reason for this may 
lie in the two relatively featureless datasets of DTIC [mean log GI50(SD) = –4.30(0.28), range = 0.99, 
high conc. = 104 M; mean log GI50(SD) = –3.66(0.548), range = 2.55, high conc. = 10–3 M] and a shared 
sensitivity in the leukemia sub-panel. Simple COMPARE using DTIC GI50 (high conc. = 10-3 M) data 
as seed in the Standard Agents database yields no correlations P>0.537. 
 
 2d 3c 3d 3e TMZ MTZ DTIC MEL CHB BCNU CCNU CP 
2d 1 0.83 0.79 0.77 0.50 0.42 0.62 0.35 0.33 0.25 0.08 0.27 
3c 0.83 1 0.92 0.92 0.52 0.35 0.72 0.4 0.33 0.32 0.06 0.32 
3d 0.79 0.92 1 0.81 0.46 0.38 0.64 0.36 0.29 0.27 0.05 0.35 
3e 0.77 0.92 0.81 1 0.51 0.46 0.71 0.59 0.53 0.45 0.10 0.42 
Table 2. Results of Matrix COMPARE (P values) for NCEs 2d, 3c-e with selected standard agents.  
 
Simple COMPARE analysis was performed with the Standard Agents and Molecular Targets 
databases using the GI50 data as seed, Table 3. The Standard Agents data again identified similarity 
with DTIC, as noted above. In addition, modest correlations with 6MP and 6TG appeared for all four 
compounds, which is presumably linked to residual MMR-dependence,24, 25 a property that is shared 
with MTZ and DTIC. With the exception of compound 3e, correlations in the Molecular Targets 
database were not strong. Notable amongst the correlations of analog 3e are the lymphocyte and 
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leukocyte related proteins LCP1, LRMP, RASSF5 and LAIR1 which may account for the high 
sensitivity of the leukemia sub-panel to these new compounds. Also intriguing are the correlations with 
the RAS-related proteins ARHGAP4 and RASSF5 and the moderate inverse correlation with RAB1A, 
a RAS superfamily GTPase.26  
 
All of the NCI cell lines are characterized for expression of MGMT and components of MMR.27 Plots 
of protein expression vs. log GI50 were prepared to probe correlation or inverse correlation between 
GI50 and expression of MGMT, hMLH1 (the core MMR protein) or MSH6 (the MMR domain that 
recognizes O6-alkylG-DNA damage), see Figures S6-8. For each of the compounds 2d, 3c–e, the 
graphs showed scatters with no connection between the protein expression levels and GI50: a result 
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Further in vitro evaluation 
The new compounds were further assessed in selected drug-resistant cell lines (Tables 4 and 5). 
HCT116 is a human colon carcinoma cell line that is deficient in both MGMT and MMR, in 
consequence it is insensitive to both TMZ and CP.28-30 Both mono- and bi-functional agent families 
showed considerably more potent activity than TMZ and MTZ in this cell line and, in further 
contrast, activity was retained in the p53-deficient mutant, Table 5. TMZ activity is known to be 
p53 dependent.31 Compounds were also evaluated against an isogenic pair of SNB19 GBM cell 
lines competent in MMR that either expressed MGMT, SNB19(MGMT), or were negative for 
MGMT, SNB19(vector). This pair of cell lines highlights the improvements the new bi-functional 
agents offer over TMZ. The MGMT-proficient line being remarkably insensitive to TMZ (IC50 is 
unattainable) and the new bi-functional agents showing equivalent activity against the two lines 
(IC50 6-12 µM) with increased potency against both SNB19(vector) and SNB19 (MGMT). A2058 is 
an aggressive melanoma line that is TMZ-sensitive and even so, the new bi-functional agents show 
a 10-fold increase in potency. 
 
 A2058 HCT116 SNB19(vector) SNB19(MGMT) 
2g >100 20.0 77.0 >100 
3c 5.5 12.5 11.0 12.0 
3e 2.5 5.5 6.6 7.0 
TMZ 35.5 >250 37.0 >250 
 
Table 4. IC50 (µM) for new compounds in selected TMZ-resistant cell lines using the Cyquant 
Assay (n=2).  
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 HCT116+/+a HCT116–/– a Ratio +/+: –/– 
2d 55 (8.2) 35.8 (7.1) 1.5 
2g 13.2 (14.1) 9.5 (4.8) 1.4 
3a 5.5 (1.2) 4.8 (2.1) 1.1 
3b 6.2 (n=2) 4.4 (2.7) 1.4 
3c	   28 (8.1)	   17 (5.3)	   1.6 
3e	   7.6 (2.1)	   9.9 (n=2)	   0.8 
MTZ	   60 (11.2)	   17.9 (8.9)	   3.4 
CP	   11.8 (n=2)	   1.9 (2.5)	   6.2 
Table 5. p53 Independence of chemosensitivity of HCT116 cell lines proficient and deficient in 
p53. IC50, µM (SD). a IC50 (µM) 
 
Discussion and Conclusions 
The aims of generating new imidazotetrazine prodrugs with activity independent of MGMT and 
MMR have been achieved through a rationally-designed switch in molecular mechanism. This 
complements other work, where alternative GO6-lesion dependent strategies have been pursued.29 
Two new families of mono- and bi-functional 3-anilinoethyl imidazotetrazines have been prepared. 
These were designed to shift the mechanism of action from dependence on GO6-DNA modification 
to GN7-modification. This was achieved through trapping the diazonium electrophile released on 
hydrolysis of the imidazotetrazine prodrug as an aziridinium ion. The mono-functional agent 2b is 
efficiently converted to an aziridinium ion (Scheme 2) and 2b and 3b are both DNA GN7-
alkylators.15 It is proposed, on the basis of analogy with reactive intermediates generated by 
nitrogen mustard and similar prodrugs, that biological activity is likely associated with this lesion.  
However it is not yet possible to distinguish definitively between a mechanism of action deriving 
from GN7-adduct formation and one proceeding from GO6-adducts that are resistant to MGMT-
mediated repair.  
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Screening in A2780 and A2780-cp70 cell lines showed that the new compounds are more potent 
than TMZ. The mono-functional agents are approximately equipotent with MTZ and the bi-
functional agents more active. This activity is independent of MGMT activity as determined by use 
of the MGMT inactivator PaTrin2. Dependence of the IC50 on MMR is greatly reduced from 
approximately 30-fold for TMZ to 2–5-fold for the new bi-functional agents. The Hammett plot, 
Figure 2, for the bi-functional agents demonstrates the critical rôle of the para-substituent in 
directing the reactivity and bioactivity of the compounds, consistent with the aziridinium ion 
mechanism occurring in vitro and corroborating the design principles. The data identified the p-
toluidine derivative 3b as the optimal analog for MGMT and MMR independence and potency. 
 
In the NCI60 screen, the new agents were not uniformly cytotoxic and showed distinct and 
individual patterns of response over a near 3-log range of GI50.  The patterns of biological response 
to the new agents were distinct from standard agents drawn from the imidazotetrazine, nitrogen 
mustard and nitrosourea families which, by chemical consideration, may be predicted to share 
similar mechanisms of action. For all compounds evaluated in the full 60 cell line screen, there was 
neither correlation with MLH1 or MSH6, nor inverse correlation with MGMT protein expression 
levels. Correlations in the Molecular Targets database suggest there may be a specific molecular 
mechanism that accounts for the sensitivity of the leukemia sub-panel to the new agents and, 
moreover, that activity could be linked to RAS family oncogenes. 
 
Collectively, the in vitro data show that the initial aims of improved potency and MGMT and 
MMR independence have been achieved. The switch of chemical mechanism has resulted in new 
agents that are distinct from existing imidazotetrazines, nitrogen mustards and nitrosoureas.  This  
implies that an increased diversity of tumor types may now be able to respond to drugs of the 
imidazotetrazine class. NCI60 panel data identified CP-resistant ovarian carcinoma cell lines as 
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responsive to the new agents. Chemosensitivity in selected drug-resistant colon carcinoma and 
glioma cell lines (HCT116 and SNB19) showed that there is activity against TMZ- and CP-resistant 
tumor lines of these types, and moreover, that the HCT116 response is independent of p53 status.  
The ability of cells to repair damage by the new agents is linked to the ATR and FANC pathways 
for the bi-functional and ATM and FANC pathways for mono-functional agents.32 Mutation in one 
of these genes would hypersensitize a tumour to these new agents. 
  
Overall these findings validate our understanding of the underlying chemistry of imidazotetrazine 
prodrugs. The members of our compound library are distinctive new agents, worthy of further 
development and application against a more diverse range of tumor types than TMZ. 
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Reagents were purchased from Sigma-Aldrich, Alfa Aesar and Fluka, solvents from Fisher 
Scientific.  TLC was performed on highly-purified silica gel plates with UV indicator (silica gel F245), 
manufactured by Merck and visualized under UV light (366 or 254 nm) or stained with iodine. 
Melting points were determined with an Electrothermal IA9200 digital melting point apparatus. 
Infrared data were obtained using a Perkin Elmer (Paragon 1000) FT-IR Spectrophotometer. NMR 
spectra were acquired on a JEOL GX270 Delta, or where indicated ECA600, spectrometers 
observing 1H at 270.05 and 600.17 MHz and 13C at 67.80 and 150.91 MHz respectively. 13C 
assignments were made with the aid of the DEPT135 experiment. Mass spectra were obtained 
from the EPSRC National Mass Spectrometry Service Centre at the University of Swansea, UK, 
and the Analytical Centre at the University of Bradford using a Micromass Quattro Ultima mass 
spectrometer. Elemental analyses were obtained from the Advanced Chemical and Material 
Analysis Unit at the University of Newcastle upon Tyne, UK. All compounds entering biological 
evaluation were dried in vacuo for 3–4 days ≤35 °C; ≥95% purity was adjudged by combustion 
analysis and hplc, solvation is indicated where appropriate; corresponding analytical hplc 
chromatograms and highfield 1H NMR spectra are shown in ESI. 
 
Compounds 2b and 3b were prepared as described in reference 15. 
 
Methyl 3-(4-chlorophenylamino)propanoate 12g 
General Method A: Single Conjugate Addition to Anilines. 
4-Chloroaniline (20.0 g, 157 mmol) was mixed with methyl acrylate (54.0 g, 627 mmol, 4 eq), 
cuprous chloride (1.56 g, 15.68 mmol, 0.1 eq) and AcOH (30 mL) and heated under reflux at 160 
°C for 2 h. The solvents were removed by evaporation and the residue partitioned between 
chloroform (500 mL) and water (500 mL). The organic layer was dried (MgSO4) in the presence of 
charcoal and filtered through celite. The solvents were removed leaving an oily residue. Petroleum 
 - 23 - 
 
ether (200 mL) was added and heated to reflux. The solvent was decanted and the product 
precipitated upon standing. The solid was collected by filtration, washed with petroleum ether and 
dried to give the ester (23.7 g, 71 %): 1H NMR (CDCl3) 7.11 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 6.55 (d, 
J = 8.8 Hz, 2H, 3-H & 5-H), 3.68 (OCH3), 3.41 (t, J = 7.2 Hz, 2H, CH2N), 2.61 (t, J = 7.2 Hz 2H, 
CH2CO); 13C NMR (CDCl3) 172.8 (C=O), 146.1 (C-1), 129.2 (C-2 & C-6), 122.5 (C-4), 114.3 (C-3 & 
C-5), 51.9 (OCH3), 39.7 (CH2N), 33.6 (CH2CO); MS (ES): m/z 214.1 (M+H)•+; IR (film) 3400, 1725, 
1600, 1500, 1435 cm-1. 
 
Methyl 3-(methyl(phenyl)amino)propanoate 12a15, 33  
Prepared by General Method A. Ester 12a was obtained as a colorless oil (13.3 g, 74 %). 1H 
NMR (CDCl3) 7.16 (t, 2H, J = 8.6 Hz, 3-H & 5-H), 6.64 (m, 3H, 2-H, 4-H & 6-H), 3.58 (m, 5H, CH2N 
& CH3N), 2.85 (s, 3H, OCH3), 2.49 (t, J = 7.3 Hz, 2H, CH2CO) 13C NMR (CDCl3) 172.8 (C=O), 
148.6 (C-1), 129.4 (C-3 & C-5), 116.9 (C-4), 112.6 (C-2 & C-6), 51.8 (OCH3), 48.7 (NCH2), 38.3 
(NCH3), 31.6 (CH2CO); MS (ES): m/z 194.1(M+H)•+; νmax (film) 1725s (C=O), 1175m (C-O) cm-1 
 
Methyl 3-((4-fluorophenyl)(methyl)amino)propanoate 12c 
Prepared according to General Method A. Ester 12c was obtained as an orange oil (2.22 g, 
75%). 1H NMR (CDCl3) 6.92 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, m, 2-H & 6-H), 3.65 (s, 3H, OCH3), 
3.60 (t, J = 7.3 Hz, 2H, NCH2), 2.86 (NCH3), 2.52 (t, J = 7.3 Hz, 2H, CH2CO); 13C NMR (CDCl3) 
172.8 (C=O), 155.7 (d, 1JCF = 235 Hz, C-4), 145.5 (C-1), 115.7 (d, 2JCF = 22 Hz, C-3 & C-5), 114.1 
(d, 3JCF = 7 Hz, C-2 & C-6), 51.8 (CH3O), 49.5 (CH2N), 38.7 (CH3N), 31.5 (CH2CO); MS (ES): m/z 
212.1 (M+H)•+; IR (KBr) 3025m (Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-
O) cm-1. 
 
Methyl 3-((4-chlorophenyl)(methyl)amino)propanoate 12d 
Prepared according to General Method A. Ester 12d was obtained as a yellow oil (9.1 g, 54%). 
1H NMR (CDCl3) 7.15 (d, J = 8.9 Hz, 2H, 3-H & 5-H), 6.63 (d, J = 8.9 Hz, 2H, 2-H & 6-H), 3.63 (s, 
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3H, OCH3), 3.62 (t, J = 7.2 Hz, 2H, NCH2), 2.89 (s, 3H, NCH3), 2.54 (t, J = 7.2 Hz, 2H, CH2CO); 13C 
NMR (CDCl3) 172.6 (C=O), 147.2 (C-1), 129.1 (C-3 & C-5), 121.7 (C-4), 113.9 (C-2 & C-6), 51.9 
(OCH3), 48.8 (NCH2), 38.4 (NCH3), 31.5 (CH2CO); MS (ES): m/z 228.1 (M+H)•+; IR (KBr) 3025m 
(Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O) cm-1. 
 
Methyl 3-((4-methoxyphenyl)(methyl)amino)propanoate 12e33 
According to General Method A. Ester 12e was obtained as a colorless oil (4.72 g, 58%): 1H 
NMR (CDCl3) 6.76 (d, 2H, J = 9.0 Hz, 3-H & 5-H), 6.67 (d, 2H, J = 9.0 Hz, 2-H & 6-H), 3.68 (s, 3H, 
CH3O-Ar), 3.59 (s, 3H, CH3OCO), 3.51 (t, J = 7.3 Hz, 2H, CH2N), 2.78 (s, 3H, CH3N), 2.46 (t, J = 
7.3 Hz, 2H, CH2CO); 13C NMR (CDCl3) 172.4 (C=O), 151.6 (C-4), 143.1 (C-1), 114.6 & 114.3 (C-3, 
C-5 & C2, C6), 55.3 (CH3O-Ar), 51.2 (CH3OCO), 49.4 (NCH2), 38.4 (CH3N), 30.9 (CH2CO); MS 
(ES): m/z 224.1 (M+H)•+; IR (film) 1725s (C=O), 1175m (C-O) cm-1. 
 
Methyl 3-(tert-butoxycarbonyl-(4-chlorophenyl)amino)propanoate 12f 
Ester 12g (2.27 g, 10.6 mmol) was mixed with di-tert-butyl carbonate (9.3 g, 42.6 mmol, 4 eq) in 
the absence of solvent. The mixture was heated at 100 °C for 18 h. The mixture was partitioned 
between H2O and petroleum ether. The organic phase was washed with H2O (5 x 50 mL), dried 
and evaporated to give ester 4h as an oil (3.2 g, 97%). 1H NMR (CDCl3) 7.29 (d, J = 8.8 Hz, 2H, 2-
H & 6-H), 7.11 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 3.91 (t, J = 7.2 Hz, 2H, NCH2), 3.53 (OCH3), 2.57 (t, 
J = 7.2 Hz, 2H, CH2CO), 1.41 (s, 9H, C(CH3)3); 13C NMR (CDCl3) 172.3 (OC=O), 154.4 (NC=O), 
141.0 (C-1), 130.9 (C-4), 129.1 (C-2 & C-6), 113.7 (C-3 & C-5), 79.8 (C(CH3)3), 51.8 (OCH3), 48.2 
(NCH2), 32.8 (CH2CO), 28.4 (CH3); MS (ES): m/z 314.1 (M+H)•+; IR (film) 1725s (C=O), 1175m (C-
O) cm-1. 
 
3-(4-Chlorophenylamino)propanehydrazide 13g34, 35 
General Method B: Preparation of monohydrazides. 
 - 25 - 
 
Ester 12g (3.7 g, 11.8 mmol, 1 eq) was mixed with hydrazine hydrate (5.9 g, 118 mmol, 10 eq) in 
propan-2-ol (10 mL) for 48h at RT. The volatiles were removed with evaporation to leave hydrazide 
13g as colorless oil (3.5 g, 95%). 1H NMR (DMSO-d6) 9.03 (br s, 1H, NHNH2), 7.05 (d, 2H, J = 8.9 
Hz, 2-H & 6-H), 6.53 (d, 2H, J = 8.8 Hz, 3-H & 5-H), 5.76 (br s, 1H, NH-aniline), 4.28 (s, br, 2H, 
NH2), 3.19 (t, J = 7.2 Hz, 2H, NCH2), 2.41 (t, J = 7.2 Hz, 2H, CH2CO); 13C NMR (DMSO-d6) 170.5 
(C=O), 148.0 (C-1), 129.1 (C-3 & C-5), 119.4 (C-4), 113.9 (C-2 & C-6), 39.9 (CH2N), 33.7 
(CH2CO); MS (ES): m/z 214.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 
3-(Methyl(phenyl)amino)propanehydrazide 13a 
Prepared according to General Method B. Hydrazide 13a was obtained as a colorless oil (12.7 g, 
98%). 1H NMR (CDCl3) 7.94 (br s, 1H, NH), 7.20 (t, 2H, J = 7.8 Hz, 3-H & 5-H), 6.69 (m, 3H, 2-H, 
4-H, 6-H), 3.62 (br, 4H, CH2N & NH2), 2.86 (s, 3H, CH3N), 2.33 (t, J = 6.8 Hz, 2H, CH2CO); 13C 
NMR (CDCl3) 172.5 (C=O), 148.7 (C-1), 129.4 (C-3 & C-5), 117.1 (C-4), 112.8 (C-2 & C-6), 49.2 
(NCH2), 38.6 (NCH3), 31.9 (CH2CO); MS (ES): m/z 194.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar 
C-H), 1650s (CONH) cm-1. 
 
3-((4-Fluorophenyl)(methyl)amino)propanehydrazide 13c 
Prepared according to General Method B. Hydrazide 13c was obtained as a yellow oil (2.16 g, 
97%): 1H NMR (CDCl3) 7.47 (br s, 1H, NH), 6.91 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, 2-H & 6-H), 3.56 
(t, J = 6.8 Hz, 2H, CH2N), 3.5 (br s, 2H, NH2), 2.83 (s, 3H, NCH3), 2.34 (t, J = 6.8 Hz, 2H, CH2CO); 
13C NMR (CDCl3) 172.4 (C=O), 156.0 (d, 1JCF = 237 Hz, C-4), 145.6 (C-1), 115.8 (d, 2JCF = 22 Hz, 
C-3 & C-5), 114.8 (d, 3JCF = 8 Hz, C-2 & C-6), 50.1 (CH2N), 39.3 (CH3N), 31.8 (CH2CO); MS (EI): 
m/z 212.1 (M+H)•+; IR (KBr) 3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm-1. 
 
3-((4-Chlorophenyl)(methyl)amino)propanehydrazide 13d 
Prepared according to General Method B. Hydrazide 13d was obtained as white solid (4.0 g, 
44%): 1H NMR (CDCl3) 7.15 (d, 2H, J = 8.9 Hz, 3-H & 5-H), 7.03 (s, 1H, NH), 6.62 (d, 2H, J = 8.9 
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Hz, 2-H & 6-H), 3.86 (br s, 2H, NH2), 3.63 (t, J = 6.8 Hz, 2H, CH2N), 2.88 (s, 3H, NCH3), 2.35 (t, J = 
6.8 Hz, 2H, CH2CO); 13C NMR (CDCl3) 172.2 (C=O), 147.3 (C-1), 129.2 (C-3 & C-5), 122.1 (C-4), 
114.0 (C-2 & C-6), 49.3 (NCH2), 38.8 (NCH3), 31.8 (CH2CO); MS (ES): m/z 226.9 (M+H)•+; IR (KBr) 
3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm-1. 
 
 
3-((4-Methoxyphenyl)(methyl)amino)propanehydrazide 13e  
Prepared according to General Method B. Hydrazide 13e was obtained as an oil which 
crystallized upon standing (4.5 g, 95%): 1H NMR (CDCl3) 7.63 (br s, 1H, NH), 6.80 (d, 2H, J = 9.2 
Hz, 3-H & 5-H), 6.75 (d, 2H, J = 9.2 Hz, 2-H & 6-H), 3.72 (s, 3H, CH3O-Ar), 3.47 (t, J = 6.6 Hz, 2H, 
CH2N), 3.3 (br s, 2H, NH2), 2.79 (s, 3H, NCH3), 2.33 (t, J = 6.6 Hz, 2H, CH2CO); 13C NMR (CDCl3) 
172.7 (C=O), 152.9 (C-4), 143.7 (C-1), 116.5 (C-2 & C-6), 114.9 (C-3 & C-5), 55.8 (CH3O-Ar), 50.7 
(CH2N), 40.0 (NCH3), 31.9 (CH2CO); MS (ES): m/z 224.1 (M+H)•+; IR (KBr) 3300s (NH), 3050m (Ar 
C-H), 1650s (CONH) cm-1. 
 
tert-Butyl-4-chlorophenyl(3-hydrazinyl-3-oxopropyl)carbamate 13f 
Prepared according to General Method B. Hydrazide 13f was obtained as a colorless oil (3.5 g, 
95%). 1H NMR (CDCl3) 7.76 (br s, 1H, NH), 7.22 (d, 2H, J = 7.8 Hz, 2-H & 6-H), 7.04 (d, 2H, J = 
7.8 Hz, 3-H & 5-H), 3.86 (t, J = 6.8 Hz, 2H, NCH2), 3.65 (s, br, 2H, NH2), 2.41 (t, J = 6.8 Hz, 2H, 
CH2CO), 1.41 (s, 9H, C(CH3)3); 13C NMR (CDCl3) 173.6 (C=O), 154.3 (NC=O), 141.8 (C-1), 131.1 
(C-4), 129.2 (C-2 & C-6), 114.1 (C-3 & C-5), 79.8 (C(CH3)3), 48.7 (NCH2), 34.2 (CH2CO), 20.3 




General Method C: Preparation of mono-imidazotetrazines 
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Hydrazide 13g (1.0 g, 4.68 mmol) was dissolved in dichloromethane (20 mL). Water (20 mL) was 
added followed by HCl (2.5 mL, 37%). The mixture was cooled in an ice/CaCl2 bath and a solution 
of NaNO2 (0.39 g, 56.2 mmol, 1.2 eq) in water (10 mL) was added with strong agitation at below –5 
°C. The ice bath was removed and dichloromethane (20 mL) was added. The reaction mixture was 
stirred for 40 min and the organic layer was separated, dried over MgSO4 and evaporated to give 
the crude azide 14g as an oil, identified by IR. The oil was diluted with toluene (100 mL) and 
heated under reflux for 1 h under N2. The volatile components were removed to give the crude 
isocyanate 15g as an oil. Diethylether (150 mL) was added and the mixture heated with strong 
agitation. The hot ether solution was decanted leaving an oily residue of impurities behind. The 
ether layer was evaporated to leave pure isocyanate as pale yellow oil (IR νmax 2260s). The 
isocyanate (0.1 g, 0.48 mmol) was mixed with diazo-IC 518 (0.07 g, 0.48 mmol, 1 eq) in dry DMSO 
(0.3 mL) under N2 at RT in the absence of light for 24 h. The reaction was quenched with water (10 
mL) and the resultant solid collected by filtration and washed with copious amounts of water to 
leave imidazotetrazine 2g as a brown solid (0.16 g, 29%): m.p. 160–161 °C; 1H NMR (DMSO-d6, 
600 MHz) 8.84 (s, 1H, imidazole CH), 7.82 & 7.70 (2 × br s, 2H, CONH2), 7.62 (d, J = 8.8 Hz, 2H, 
3-H & 5-H), 7.54 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.52 (t, J = 6.0 Hz, 2H, NCH2), 4.42 (t, J = 6.0 Hz, 
2H, CH2CO), 3.3 (br s, NH-aniline & H2O); 13C NMR (DMSO-d6, 151 MHz) 161.8 (C=O amide), 
140.0 (C-1), 139.4 (C=O tetrazine), 134.4 (Cq tetrazine), 132.7 (C-4), 131.8 (Cq imidazole), 130.0 
(C-3 & C-5), 129.5 (C-H imidazole), 122.3 (C-2 & C-6), 45.9 (CH2N-aniline), 42.0 (CH2N-tetrazine); 
MS (ES): m/z 334.1 (M+H)•+; IR (KBr) 3450m & 3300 (CONH2), 1750s (C=O), 1650s (CONH2), 




Prepared according to General Method C. The product was purified by flash column 
chromatography (2% MeOH/CHCl3) and imidazotetrazine 2a was obtained as a white solid (0.34 g, 
21%): m.p. 186–187 °C. 1H NMR (DMSO-d6, 600 MHz) 8.77 (s, 1H, imidazole CH), 7.79 & 7,68 (2 
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× br s, 2H, CONH2), 7.06 (t, J = 8.6 Hz, 2H, 3-H & 5-H), 6.68 (d, J = 8.6 Hz, 2H, 2-H & 6-H), 6.50 (t, 
J = 8.6 Hz, 1H, 4-H), 4.46 (t, J = 6.4 Hz, 2H, NCH2), 3.80 (t, J = 6.4 Hz, 2H, CH2CO), 2.91 (s, 3H, 
NCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 148.9 (C-1), 139.6 (C=O tetrazine), 134.7 
(Cq tetrazine), 131.3 (Cq imidazole), 129.4 (C-3 & C-5), 129.2 (C-H imidazole), 116.6 (C-4), 112.4 
(C-2 & C-6), 50.3 (CH2N-aniline), 46.4 (CH2N-tetrazine), 38.3 (CH3); MS (ES): m/z 314.2 (M+H)•+; 
627.4 (2M+H) •+; IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 1600m (Ar-H) cm-1. 




Prepared by General Method C. The product was precipitated with water, collected by filtration 
and the crude solid dried and suspended in chloroform (20 mL). The impurities were removed by 
filtration and the filtrate evaporated to yield imidazotetrazine 2d as a yellow solid (0.084 g, 25%): 
m.p. 154–155 °C 1H NMR (DMSO-d6, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.75 & 7.65 (2 × br s, 
2H, CONH2), 7.07 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 6.66 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.43 (t, J = 
6.6 Hz, 2H, CH2N), 3.77 (t, J = 6.6 Hz, 2H, CH2CO), 2.87 (s, 3H, NCH3); 13C NMR (151 MHz, 
DMSO-d6) 161.9 (CONH2), 147.8 (C-1), 139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq 
imidazole), 129.2 (C-H imidazole), 129.1 (C-3 & C-5), 120.3 (C-4), 113.9 (C-2 & C-6), 50.4 (CH2N-
aniline), 46.3 (CH2N-tetrazine), 38.5 (CH3); MS (ES): m/z 348.2 (M+H)•+; 695.3 (2M+H)•+; 717.3 
(2M+Na)•+; IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 1600m & 1500s (Ar-H) cm-1. 
Anal. C14H14ClN7O2·0.5 H2O, CHN. 
 
tert-Butyl 2-(8-carbamoyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-3(4H)-yl)ethyl(4-
chlorophenyl) carbamate 2f 
Prepared according to General Method C. The product was purified by flash column 
chromatography (10% AcOH/CHCl3) and imidazotetrazine 2f was obtained as a white solid (0.15 g, 
51%): m.p. 177–178 °C; 1H NMR (DMSO-d6, 600 MHz) 8.91 (s, 1H, imidazole CH), 7.83 & 7.70 (2 
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× br s, 2H, CONH2), 7.40 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 7.32 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 4.40 
(t, J = 6.7 Hz, 2H, NCH2), 4.04 (t, J = 6.5 Hz, 2H, CH2CO), 1.11 (s, 9H, C(CH3)3); 13C NMR (DMSO-
d6, 151 MHz) 161.8 (CONH2), 154.3 (N(CO)O), 140.8 (C-1), 139.6 (CO tetrazine), 134.6 (Cq 
tetrazine), 131.4 (Cq imidazole), 131.0 (C-4), 129.4 (C-H imidazole), 129.2 & 129.1 (C-3 & C-5,C-2 
& C-6), 80.74 (C(CH3)3), 48.3 & 48.0 (CH2N-tetrazine & CH2N-aniline), 28.0 (CH3); MS (ES): m/z 
434.3 (M+H)•+; 456.2 (M + Na)•+; IR (KBr) 3450m (CONH2), 3150m (CONH2), 1750s (C=O), 1700s 




Prepared according to General Method C from hydrazide 13b. On completion of the reaction, the 
mixture was quenched with propan-2-ol (10 mL) and the solid collected by filtration and washed 
with propan-2-ol then methanol to leave imidazotetrazine 2h as an orange solid (0.43 g, 24%): m.p. 
133–134 °C. 1H NMR (DMSO-d6, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.77 & 7,66 (2 × br s, 2H, 
CONH2), 7.38 (d, J = 2.0 Hz, 1H, 2-H), 7.20 (d, J = 8.4 Hz, 1H, 5-H), 7.14 (br d, J = 8.4 Hz, 1H, 6-
H), 4.44 (t, J = 6.2 Hz, 2H, CH2N-aniline), 3.45 (t, J = 6.2 Hz, 2H, CH2N-tetrazine), 2.75 (s, 3H, 
NCH3), 2.12 (s, 3H, ArCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 143.0 (C-3), 142.5 (C-
1), 139.4 (C=O tetrazine), 134.6 (Cq tetrazine), 134.3 (C-2), 131.4 (Cq imidazole), 131.3 (C-4), 
129.2 (C-H imidazole), 125.3 (C-6), 121.8 (C-5), 53.4 (CH2N-aniline), 46.4 (CH2N-tetrazine), 40.7 





Prepared according to General Method C from 13e. The product was purified by flash column 
chromatography (10% AcOH/CHCl3). The solid was washed with 50% MeOH/H2O and 
imidazotetrazine 2i was obtained as a purplish red solid (0.21 g, 26%): m.p. 166–168 °C. 1H NMR 
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(DMSO-d6, 600 MHz) 8.80 (s, 1H, imidazole CH), 7.79 & 7.67 (2 × br s, 2H, CONH2), 7.36 (d, J = 
8.9 Hz, 1H, 6-H), 7.18 (d, J = 3.0 Hz, 1H, 3-H), 7.07 (dd, J = 3.0, 8.9 Hz, 1H, 5-H), 4.42 (t, J = 6.0 
Hz, 2H, CH2N-aniline), 3.68 (s, 3H, OCH3) 3.35 (t, J = 6.0 Hz, 2H, CH2N-tetrazine), 2.70 (s, 3H, 
NCH3); 13C NMR (DMSO-d6, 151 MHz) 162.0 (CONH2, 155.2 (C-4), 145.8 (C-2), 139.4 (C=O 
tetrazine), 138.6 (C-1), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.2 (C-H imidazole), 125.1 
(C-6), 119.9 (C-3), 108.9 (C-5), 56.4 (CH3O), 54.5 (CH2N-aniline), 46.6 (CH2N-tetrazine), 42.0 
(NCH3); MS (ES): m/z 389.2 (M+H)•+; 411.2 (M + Na)•+; IR (KBr) 3425m (CONH2), 3150m 
(CONH2), 1750s (C=O), 1700s (CONH2), 1600m & 1525s (Ar-H) cm-1. Anal. C15H16N8O5·0.1 H2O, 
CHN. 
 




3-(N-(4-Fluorophenyl)-N-methylamino)propanoyl azide 14c 
Hydrazide 13c (0.25 g, 1.2 mmol) was dissolved in a mixture of AcOH (0.66M 15 mL) and DCM 
(15 mL), the mixture was then stirred on a CaCl2-ice bath at 0 ºC, a solution of NaNO2 (0.49 g, 7.1 
mmol) in H2O (25 mL) was added dropwise keeping the exothermic reaction at 0–5 ºC. A further 
amount of DCM (20 mL) was added, the DCM layer separated, washed with H2O (20 mL) dried 
over MgSO4, then filtered. Formation of azide 14c was confirmed by IR. 1H NMR (CDCl3, 600 
MHz): 6.93 (t, 2H, JHH = 3JHF = 9.1 Hz, 3',5'-H), 6.66 (dd, 2H, JHH = 9.1 Hz, 4JHF = 4.3 Hz, 2',6'-H), 
3.60 (t, 2H, J = 7.1 Hz, 3-H), 2.86 (s, 3H, NCH3), 2.55 (t, 2H, J = 7.1 Hz, 2-H); 13C NMR (CDCl3, 
151 MHz) 179.2 (C-1), 155.3 (d, 1JCF = 237 Hz, C-4'), 145.2 (C-1'), 115.8 (d, 2JCF = 21.7 Hz, C-
3',5'), 114.3 (d, 3JCF = 7.2 Hz, C-2',6'), 49.4 (C-3), 38.9 (NCH3), 34.2 (C-2); IR (liq. film) 2914w (CH 
st), 2137s (CON3), 1711s (CO), 1511m (C=C), 815s (p-di-substituted aromatic ring) cm-1. 
 
2-(N-(4-Fluorophenyl)-N-methylamino)ethyl isocyanate 15c  
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The anhydrous DCM solution of azide 14c was stirred under nitrogen at RT overnight. 
Isocyanate 15c formation was confirmed by IR and 1H NMR. The DCM was evaporated under 
reduced pressure at low temperature (an ice bath was used to lower the temperature). The 
isocyanate was collected as a yellow oil (0.2 g, 77%). 1H NMR (CDCl3, 600 MHz) 6.95 (t, 2H, JHH = 
3JHF = 9.1 Hz, 3',5'-H), 6.69 (dd, 2H, JHH = 9.1 Hz, 4JHF = 4.3 Hz, 2',6'-H), 3.43 (m, 4H, 1,2-H), 2.94 
(s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz) 157.2 (NCO), 155.3 (d, 1JCF = 237 Hz, C-4'), 145.2 (C-
1'), 115.8 (d, 2JCF = 21.7 Hz, C-3',5'), 114.4 (d, 3JCF = 7.2 Hz, C-2',6'), 54.5 (C-3), 40.9 (C-2), 39.6 
(NCH3); IR (liq film) 3057w (Ar-CH st), 2917w (CH st), 2270s (NCO), 1512m (C=C), 1228m, 816s 




Isocyanate 15c (0.2 g, 1.03 mmol) was diluted with DMSO (1.5 mL) under nitrogen then added 
to a suspension of diazo-IC 5 (0.14 g, 1.03 mmol) in DMSO (1.5 mL), the mixture was stirred at rt 
protected from light for 48 h. The 1H NMR spectrum showed product 2c formation. The reaction 
mixture was suspended in H2O (30 mL) and filtered, the residue was washed with copious 
amounts of H2O until the washings came through colorless and then washed with Et2O. The solid 
was purified by flash column chromatography, 10% AcOH in CHCl3 was used for the elution; the 
fractions containing the product were evaporated to give an orange solid. The solid was then re-
dissolved in CHCl3 and filtered, the CHCl3 evaporated and the residue re-suspended in Et2O and 
then collected by filtration to give 2c (0.057 g, 17%), m.p. 172–173 ºC . 1H NMR (DMSO-d6, 600 
MHz): 8.77 (s, 1H, 6-H), 7.75 & 7.65 (2 × br s, 2H, CONH2), 6.91 (t, 2H, JHH = JHF = 9.1 Hz, 3',5'-H), 
6.69 (dd, 2H, JHH = 9.1 Hz, JHF = 4.3 Hz, 2',6'-H), 3.45 (t, 2H, J = 6.4 Hz, 1-H), 3.77 (t, 2H, J = 6.4 
Hz, 2-H), 2.90 (s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz) 161.89 (CONH2), 155.0 (d, 1JCF = 235.5 
Hz, C-4'), 145.9 (C-1'), 139.5 (C-4), 134.7 (C-8a), 131.3 (C-8), 129.2 (C-6), 115.7 (d, 2JCF = 21.7 
Hz, C-3',5'), 113.6 (d, 3JCF = 7.2 Hz, C-2',6'), 50.9 (C-2), 46.3 (C-1) 38.7 (NCH3); IR (KBr) 3439s 
(NH), 3117m (Ar-CH st), 2914w (CH st), 1749s (C(4)O), 1682s (CONH2), 1515 s, 1458m (C=C), 
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820m (p-di-substituted aromatic ring) cm-1; MS (ES): m/z 331.9 (20%) (M+H)+, 353.9 (10%) 
(M+Na)+, 195.0 (100%) (C10H11FN2O+H)+. Anal. C14H14FN7O2·0.75H2O, CHN. 
 
Modified Procedure for tetrazine 2e 
 
3-(N-Methyl-N-(4-nitrophenyl)amino)propanoyl azide 14e and 
3(N-methyl-N-(2-nitrophenyl)amino)propanoyl azide  
Hydrazide 13a (0.3g, 1.6 mmol) was dissolved in a mixture of DCM (10 mL) and HCl (10 mL, 
14.8%), the solution was stirred at 0 ºC on a CaCl2-ice bath, NaNO2 (0.66 g, 9.6 mmol) solution in 
H2O (10 mL) was added gradually, keeping the exothermic reaction between 0–5 ºC. A further 
portion of DCM (15 mL) was added, the DCM layer was separated, washed with two portions of 
H2O (20 mL) dried over MgSO4, then filtered. Formation of the azide 14e was confirmed by IR and 
1H NMR which also showed the formation of small amount of the ortho-nitrated azide in ratio 1:5. 
Azide 14e 1H NMR (CDCl3, 600 MHz) 8.12 (½AB, 2H, J = 9.5 Hz, 3',5'-H), 6.61 (½AB, 2H, J = 9.5 
Hz, 2',6'-H), 3.77 (t, 2H, J = 7.0 Hz, 3-H), 3.10 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.0 Hz, 2-H); 13C NMR 
(CDCl3) δ: 178.5 (CON3), 152.8 (C-4'), 133.2 (C-1'), 126.4 (C-3',5'), 110.6 (C-2',6'), 48.0 (C-3), 39.1 
(NCH3), 34.4 (C-2); IR (liq film) 2918w (CH st), 2140s (N3), 1711s (CO), 1597s (NO2 st as), 1518 s 
(C=C), 1311s (NO2 st) cm-1. o-NO2-Azide: 1H NMR (CDCl3, 600 MHz): 7.72 (d, 1H, J = 8.9 Hz, 5'-
H), 7.42 (t, 1H, J = 8.9 Hz, 4'-H), 7.21 (d, 1H, , J = 8.9 Hz, 2'-H ), 6.96 (t, 1H, J = 8.9 Hz, 3'-H), 3.46 
(t, 2H, J = 7.1 Hz, 3-H), 2.80 (s, 3H, NCH3) 2.62 (t, 2H, J = 7.1 Hz, 2-H). 
 
2-[(4-Nitrophenyl)methylamino]ethylisocyanate 15e 
The anhydrous DCM solution of the crude azide 14e was stirred under nitrogen at RT overnight. 
Isocyanate formation was confirmed by IR. The DCM was evaporated under reduced pressure at 
low temperature (an ice bath was used to lower the temperature) and the crude isocyanate 15e 
collected as a yellow oil (0.27 g, 90 %). 1H NMR (CDCl3, 600 MHz) 8.15 (½AB, 2H, J = 9.4 Hz, 
3',5'-H), 6.67 (½AB, 2H, J = 9.4 Hz, 2',6'-H), 3.66 (t, 2H, J = 6.2 Hz, 2-H), 3.57 (t, 2H, J = 6.2 Hz, 1-
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H), 3.15 (s, 3H, NCH3); 13C NMR (CDCl3, 151 MHz)153.1 (NCO), 145.2 (C-4'), 138.1 (C-1'), 126.4 
(C-3',5'), 110.7 (C-2',6'), 52.6 (C-2), 40.7 (C-1) , 39.5 (NCH3); IR (liq film) 2919w (CH st), 2270s 
(NCO), 1597s (NO2 st as), 1517 s (C=C), 1311s (NO2 st) cm-1. Isocyanate ortho-nitro isomer: 1H 
NMR (CDCl3, 600 MHz) 7.74 (d, 1H, J = 8.4 Hz, 5'-H), 7.45 (t, 1H, , J = 8.4 Hz, 4'-H), 7.18 (d, 1H, , 
J = 8.4 Hz, 2'-H ), 6.99 (t, 1H, J = 8.9 Hz, 3'-H), 3.48 (t, 2H, J = 6.0 Hz, 3-H), 2.90 (s, 3H, NCH3), 
3.31 (t, 2H, J = 7.1 Hz, 2-H). 
 
3-(2-N-Methyl-N-(4-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-
d][1,2,3,5]tetrazine-8-carboxamide 2e and 
3-(2-(N-methyl-N-(2-nitrophenyl)-N-methylamino)ethyl)-4-oxo-3H,4H-
imidazo[5,1d][1,2,3,5]tetrazine-8-carboxamide  
The crude mixture of the isocyanate 15e (0.27 g, 1.22 mmol) was diluted with DMSO (1.5 mL) 
under N2 then added to a suspension of diazo-IC 5 (0.17 g, 1.22 mmol) in DMSO (1.5 mL), the 
mixture was stirred at RT protected from light for 48 h. The reaction mixture was then suspended in 
water (30 mL) and filtered. The solid on the filter was washed with copious amounts of H2O until 
the washings came through colorless, then with Et2O. The dry solid was purified by flash column 
chromatography eluted with a gradient 5–20% AcOH in CHCl3. 1H NMR showed impurities from 
silica, so the imidazotetrazinone solid was dissolved in DMF, filtered and the imidazotetrazinone 
precipitated as a yellow solid by H2O addition. The solid was collected by filtration, washed with 
copious amounts of water and then dried to give 2e (0.025g, 6 %), m.p. 179–180 ºC. 1H NMR 
(DMSO-d6, 600 MHz)8.81 (s, 1H, 6-H), 8.00 (½AB, 2H, J = 9.2 Hz, 3',5'-H), 7.77 & 7.67 (2 × br s, 
2H, CONH2), 6.82 (½AB, 2H, J = 9.2 Hz, 2',6'-H), 4.52 (t, 2H, J = 6.3 Hz, 1-H), 3.96 (t, 2H, J = 6.3 
Hz, 2-H), 3.07 (s, 3H, NCH3); 13C NMR (DMSO-d6, 151 MHz) 161.9 (CONH2), 154.0 (C-4'), 139.7 
(C-4), 136.6 (C-1'), 134.7 (C-8a), 131.6 (C-8), 129.5 (C-6), 126.3 (C-3',5'), 111.4 (C-2',6'), 50.3 (C-
2), 46.4 (C-1) 39.2 (NCH3); IR (KBr) 3443m (NH), 2919w (CH st), 1749s (C(4)O), 1684s (CONH), 
1597s (NO2 st as), 1457m (C=C), 1316s (NO2 st) cm-1; MS(ES): m/z 359.1(80%) (M+H)+, 
381.1(100%) (M+Na)+; Anal. C14H14N8O4 ·0.6 AcOH·0.2 CHCl3, CHN. 
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meta-NO2 isomer: 1H NMR (DMSO-d6, 600 MHz) 8.83 (s, 1H, 6-H), 7.83 & 7.71 (2 × br s, 2H, 
CONH2), 7.65 (d, 1H, J = 9.1 Hz, 5'-H), 7.46 (t, 1H, J = 9.1 Hz, 4'-H), 7.31 (t, 1H, J = 9.1 Hz, 2'-H), 
6.92 (d, 1H, J = 9.1 Hz, 3'-H), 4.52 (t, 2H, J = 6.1 Hz, 1-H), 3.59 (t, 2H, J = 6.1 Hz, 2-H), 2.83 (s, 
3H, NCH3). 
 
Dimethyl 3,3'-(4-chlorophenylazanediyl)dipropanoate 8d36 
General Method D: Double Conjugate addition to anilines. 
4-Chloroaniline (10 g, 78.4 mmol) was mixed with methyl acrylate (67.5 g, 784 mmol, 10 eq), 
cuprous chloride (1.24 g, 12.5 mmol, 0.16 eq) and AcOH (100 mL) and heated under reflux at 140 
°C for 48 h. The reaction mixture was allowed to reach RT and water (300 mL) was added with 
strong agitation. The batch was allowed to stand in the fridge overnight and the water layer was 
decanted leaving the oil behind. The oil was washed with more water (2 × 300 mL), diluted with 
diethylether (200 mL), washed with water (300 mL), dried over MgSO4 and evaporated to give 
diester 8d as a light brown oil (19.0 g, 88%). 1H NMR (CDCl3) 7.17 (d, J = 8.8 Hz, 2H, 3-H & 5-H), 
6.68 (d, J = 8.8 Hz, 2H, 2-H & 6-H), 3.65 (s, 6H, 2 x CH3), 3.61 (t, J = 7.2 Hz, 4H, 2 x CH2N), 2.57 
(t, J = 7.2 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.3 (C=O), 145.0 (C-1), 129.4 (C-3 & C-5), 
129.3 (C-4), 114.1 (C-2 & C-6), 51.9 (CH3), 47.2 (NCH2), 32.1 (CH2CO); MS (ES): m/z 300.1 
(M+H)•+; IR (film) 1725s (C=O), 1175m (C-O) cm-1. 
 
Dimethyl 3,3'-(phenylazanediyl)dipropanoate 8a37 
Prepared according to General method D. Diester 8a was obtained as an orange oil (18.8 g, 
67%). 1H NMR (CDCl3) 7.16 (m, 2H, 3-H & 5-H), 6.62 (m, 3H, 2-H, 4-H, 6-H), 3.60 (m, 10H, 2 x 
CH2N-aniline & 2 x OCH3), 2.52 (t, J = 7.1 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.6 (C=O), 
146.7 (C-1), 129.6 (C-3 & C-5), 117.2 (C-4), 112.6 (C-2 & C-6), 51.8 (CH3), 47.0 (NCH2), 32.3 
(CH2CO); MS (ES): m/z 266.1 (M+H)•+; IR  (film) 1725s (C=O), 1175m (C-O) cm-1. 
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Dimethyl 3,3'-(4-fluorophenylazanediyl)dipropanoate 8c37 Prepared according to General 
Method D. Diester 8c was obtained as a yellow oil (0.99 g, 75%). 1H NMR (CDCl3) 6.92 (m, 2H, 3-
H & 5-H), 6.74 (m, 2H, m, 2-H & 6-H), 3.64 (s, 6H, 2 x CH3), 3.56 (t, J = 7.2 Hz, 4H, 2 x CH2N), 
2.52 (t, J = 7.2 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 172.6 (C=O), 156.0 (d, 1JCF = 237 Hz, C-4), 
143.5 (C-1), 115.9 (d, 2JCF = 22 Hz, C-3 & C-5), 114.9 (d, 3JCF = 7 Hz, C-2 & C-6), 51.8 (CH3), 47.7 
(CH2N), 32.3 (CH2CO); 19F NMR (CDCl3) –127.62; MS (ES): m/z 284.0 (M+H)•+; IR  (KBr) 3025m 
(Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O), cm-1. 
 
Dimethyl 3,3'-(4-methoxyphenylazanediyl)dipropanoate 8e37 
Prepared according to General Method D. Diester 8e was obtained as an orange oil (21.7 g, 
90%). 1H NMR (CDCl3) 6.84 (d, 2H, J = 8.1 Hz, 3-H & 5-H), 6.74 (d, 2H, J = 8.1 Hz, 2-H & 6-H), 
3.75 (s, 3H, CH3), 3.64 (s, 6H, 2 x CH3), 3.53 (t, J = 7.1 Hz, 4H, 2 x NCH2), 2.51 (t, J = 7.1 Hz, 4H, 
2 x CH2CO); 13C NMR (CDCl3) 175.4 (C=O), 152.9 (C-4), 141.0 (C-1), 121.4 (C-3 & C-5), 114.9 (C-
2 & C-6), 55.8 (CH3), 51.9 (CH3), 50.5 (NCH2), 33.5 (CH2CO); MS (ES): m/z 296.1 (M+H)•+; IR  




General Method E: Preparation of bis-hydrazides 
Diester 8d (19 g, 63.4 mmol) was mixed with hydrazine hydrate (12.6 g, 0.25 mol, 4 eq) in 
propan-2-ol (60 mL) for 48 h at RT. The resulting solid was collected by filtration, washed with 
propan-2-ol and dried in vacuo to give hydrazide 10d as white solid (18.8 g, 99%): 1H NMR 
(DMSO-d6) 9.03 (s, 2H, 2 x NH), 7.15 (d, 2H, J = 9.1 Hz, 3-H & 5-H), 6.66 (d, 2H, J = 9.1 Hz, 2-H & 
6-H), 4.18 (br s, 4H, 2 x NH2), 3.46 (t, J = 7.2 Hz, 4H, 2 x NCH2), 2.23 (t, J = 7.2 Hz, 4H, 2 x 
CH2CO); 13C NMR (DMSO-d6) 170.4 (C=O), 146.4 (C-1), 129.3 (C-3 & C-5), 119.8 (C-4), 113.8 (C-
2 & C-6), 47.4 (NCH2), 31.9 (CH2CO); MS (ES): m/z 300.1 (M+H)•+; IR  (KBr) 3300s (NH), 3050m 
(Ar C-H), 1650s (CONH) cm-1. 




Prepared according to General Method E. Hydrazide 10a was obtained as a white solid (6.3 g, 
72%). 1H NMR (DMSO) 9.04 (s, 2H, 2 x NH), 7.15 (t, 2H, J = 7.4 Hz, 3-H & 5-H), 6.66 (d, 2H, J = 
7.4 Hz, 2-H & 6-H), 6.58(t, 2H, J = 7.4 Hz, 4-H), 4.18 (br s, 4H, 2 x NH2), 3.48 (t, J = 7.2 Hz, 4H, 2 x 
CH2N), 2.25 (t, J = 7.2 Hz, 4H, 2 x CH2CO); 13C NMR (DMSO) 170.5 (C=O), 147.6 (C-1), 129.7 (C-
3 & C-5), 116.2 (C-4), 112.4 (C-2 & C-6), 47.4 (NCH2), 32.1 (CH2CO); MS (ES): m/z 266.1 (M+H)•+; 
IR  (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 
3,3'-(4-Fluorophenylazanediyl)dipropanehydrazide 10c 
Prepared according to General Method E. Hydrazide 10c was obtained as a white solid (0.63 g, 
64%): m.p. 131.4 °C. 1H NMR (DMSO-d6) 8.91 (br s, 2H, 2 x NH), 6.88 (m, 2H, 3-H & 5-H), 6.56 
(m, 2H, 2-H & 6-H), 4.07 (br s, 4H, 2 x NH2), 3.33 (t, J = 7.2 Hz, 4H, 2 x CH2N), 2.11 (t, J = 7.2 Hz, 
4H, 2 x CH2CO); 13C NMR (DMSO-d6) 170.5 (C=O), 154.8 (d, 1JCF = 228 Hz, C-4), 144.5 (C-1), 
116.0 (d, 2JCF = 22 Hz, C-3 & C-5), 113.7 (d, 3JCF = 7 Hz, C-2 & C-6), 47.8 (CH2N), 31.9 (CH2CO); 
19F NMR (CDCl3) –129.53; MS (EI): m/z 283.0 (M+H)•+; νmax (KBr) 3300m (NH), 3050m (Ar C-H), 
1650s (CONH), 1525m (Ar C=C) cm-1 
 
3,3'-(4-Methoxyphenylazanediyl)dipropanehydrazide 10e 
Prepared according to General Method E. Hydrazide 10e was obtained as a white solid (20.5 g, 
95%): 1H NMR (CDCl3) 7.39 (br s, 2H, 2 x NH), 6.85 (d, 2H, J = 8.1 Hz, 3-H & 5-H), 6.80 (d, 2H, J 
= 8.1 Hz, 2-H & 6-H), 4.10 (br s, 4H, 2 x NH2), 3.75 (s, 3H, CH3), 3.32 (t, J = 7.1 Hz, 4H, 2 x CH2N), 
2.28 (t, J = 7.1 Hz, 4H, 2 x CH2CO); 13C NMR (CDCl3) 173.4 (C=O), 155.0 (C-4), 142.4 (C-1), 
121.4 (C-3 & C-5), 114.7 (C-2 & C-6), 55.6 (CH3), 50.7 (NCH2), 33.3 (CH2CO); MS (ES): m/z 296.1 
(M+H)•+; νmax (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm-1. 
 




General Method F: Preparation of bis-imidazotetrazines 
Hydrazide 10d (1.0 g, 3.18 mmol, 1 eq) was dissolved in dichloromethane (10 mL). Water (10 
mL) was added followed by HCl (2.5 mL, 37 %). The mixture was cooled in an ice/CaCl2 bath and 
a solution of NaNO2 (0.57 g, 8.26 mmol, 2.6 eq) in water (10 mL) was added with strong agitation 
below 5 °C. After the addition, the reaction was allowed to reach RT and stirred overnight. The 
organic layer was separated, dried over MgSO4 and evaporated to give the azide 11d as a crude 
oil, identified by IR. The oil was diluted with toluene (100 mL) and heated under reflux for 2 h under 
N2. The volatile components were removed to give the crude isocyanate 9d as an oil. Diethylether 
(150 mL) was added and the mixture heated with strong agitation. The hot solution was decanted 
leaving a residue of oily impurities behind. The ether was evaporated to leave pure isocyanate as 
pale yellow oil (IR νmax 2260s). The isocyanate (0.29g, 1.03 mmol) was mixed with diazo-IC 5 (0.3 
g, 2.17 mmol, 2.1 eq) in dry DMSO (0.1 mL) under N2 at RT in the absence of light for 24 h. The 
bis-imidazotetrazine was purified by flash column chromatography eluting with CHCl3:AcOH (1:1) 
to give imidazotetrazine 3d as a light brown solid (0.1 g, 6%): m.p. 143-144 °C. 1H NMR (DMSO-
d6, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 (2 × br s, 4H, 2 × CONH2), 7.09 (d, J = 8.9 
Hz, 2H, 3-H & 5-H), 6.80 (d, J = 8.9 Hz, 2H, 2-H & 6-H), 4.42 (t, J = 6.6 Hz, 4H, 2 x NCH2 aniline), 
3.78 (t, J = 6.6 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 
146.2 (C-1), 140.0 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq imidazole), 2 x 129.3 (C-3 & C-
5, C-H imidazole), 120.9 (C-4), 114.2 (C-2 & C-6), 49.1 (CH2N-aniline), 46.4 (CH2N-tetrazine); MS 
(ES): m/z 540.2 (M+H)•+; 562.3 (M + Na)•+; IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s 
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Prepared according to General Method F. The product was purified by flash column 
chromatography (5% AcOH/CH3CN) and imidazotetrazine 3a was obtained as a yellow solid (0.38 
g, 60%): m.p. 194–195 °C; 1H NMR (DMSO-d6, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 
(2 × br s, 4H, 2 × CONH2), 7.06 (t, J = 7.5 Hz, 2H, 3-H & 5-H), 6.80 (d, J = 7.5 Hz, 2H, 2-H & 6-H), 
6.51 (t, J = 7.5 Hz, 1H, 4-H), 4.44 (t, J = 6.9 Hz, 4H, 2 x CH2N-aniline), 3.79 (t, J = 6.9 Hz, 4H, 2 x 
CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 147.2 (C-1), 139.7 (C=O 
tetrazine), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.6 & 129.3 (C-3 & C-5, C-H imidazole), 
117.1 (C-4), 112.5 (C-2 & C-6), 48.8 (CH2N-aniline), 46.6 (CH2N-tetrazine); MS (ES): m/z 506.3 
(M+H)•+; νmax (KBr) 3450m & 3150m (CONH2), 1740s (C=O), 1675s (CONH2), 1600m & 1510s (Ar-




Prepared according to General Method F. Imidazotetrazine 3c was obtained as dark yellow solid 
(0.04 g, 42%): m.p. 290–291 °C; 1H NMR (DMSO-d6, 600 MHz) 8.78 (s, 2H, imidazole CH), 7.77 & 
7.66 (2 × br s, 4H, 2 × CONH2), 6.91 (m, 2H, 3-H & 5-H), 6.80 (m, 2H, 2-H & 6-H), 4.41 (t, J = 6.7 
Hz, 4H, 2 x CH2N-aniline), 3.76 (t, J = 6.7 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 
MHz) 161.9 (C=O amide), 155.0 (d, 1JCF = 243 Hz, C-4), 144.1 (C-1), 139.7 (C=O tetrazine), 134.7 
(Cq tetrazine), 131.3 (Cq imidazole), 129.3 (C-H imidazole), 116.0 (d, 2JCF = 23.1 Hz, C-3 & C-5), 
114.1 (d, 3JCF = 7.2 Hz, C-2 & C-6), 49.4 (CH2N-aniline), 46.5 (CH2N-tetrazine); MS (ES): m/z 524.3 
(M+H)•+; 546.2 (M + Na) •+;  IR (KBr) 3450m (CONH2), 1725s (C=O), 1675s (CONH2), 1600m & 




Prepared according to General Method F. The product was purified by flash column 
chromatography (5% AcOH/CH3CN) and imidazotetrazine 3f was obtained as an orange/yellow 
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solid (0.21 g, 26%): m.p. 139–140 °C. 1H NMR (DMSO-d6, 600 MHz) 8.72 (s, 2H, imidazole CH), 
7.77 & 7.67 (2 × br s, 4H, 2 × CONH2), 7.49 (d, J = 9.2 Hz, 1H, 6-H), 7.16 (d, J = 3.0 Hz, 1H, 3-H), 
7.04 (dd, J = 9.2, 3.0 Hz, 1H, 5-H), 4.32 (t, J = 6.2 Hz, 4H, 2 x CH2N-aniline), 3.67 (s, 3H, OCH3), 
3.47 (t, J = 6.2 Hz, 4H, 2 x CH2N-tetrazine); 13C NMR (DMSO-d6, 151 MHz) 161.9 (C=O amide), 
156.3 (C-4), 147.8 (C-2), 139.5 (C=O tetrazine), 135.6 (C-1), 134.8 (Cq tetrazine), 131.3 (Cq 
imidazole), 129.1 (C-H imidazole), 126.9 (C-5), 119.4 (C-6), 109.1 (C-3), 56.4 (CH3O), 52.1 (CH2N-
aniline), 46.9 (CH2N-tetrazine); MS (ES): m/z 581.3 (M+H)•+; 603.1 (M + Na)•+; IR (KBr) 3450m 
(CONH2), 1750s (C=O), 1675s (CONH2), 1600m & 1525s (Ar-H) cm-1. Anal. C21H20N14O7·1.4 




Prepared by a variation on General Method F using AcOH (0.17 M) in place of HCl. The product 
was purified by flash column chromatography (10% AcOH/CHCl3) and 3e was obtained as red 
solid (0.2 g, 11%): m.p. 178-179 °C. 1H NMR (DMSO-d6, 600 MHz) 8.75 (s, 2H, imidazole CH), 
7.76 & 7,65 (2 × br s, 4H, 2 × CONH2), 6.73 (d, J = 8.1 Hz, 2H, 3-H & 5-H), 6.62 (d, J = 8.1 Hz, 2H, 
2-H & 6-H), 4.39 (t, J = 6.6 Hz, 4H, 2 x CH2N-aniline), 3.72 (t, J = 6.6 Hz, 4H, 2 x CH2N-tetrazine), 
3.53(s, 3H, CH3); 13C NMR (DMSO-d6, 151 MHz) 162.0 (C=O amide), 152.0 (C-4), 141.5 (C-1), 
139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.2 (Cq imidazole), 129.2 (C-H imidazole), 115.2 & 
114.9 (C-2 & C-6, C-3 & C-5), 55.6 (CH3), 49.6 (CH2N-aniline), 46.9 (CH2N-tetrazine); MS (ES): 
m/z 536.3 (M+H)•+; 558.3 (M + Na)•+;  IR (KBr) 3450m (CONH2), 1750s (C=O), 1675s (CONH2), 
1600m & 1500s (Ar-H) cm-1. Anal. C21H21N13O5, CHN. 
 
In vitro Chemosensitivty 
Cells used were A2780 (human ovarian carcinoma, from European Collection of Cell Cultures), 
the MMR-deficient derivative A2780-Cp70 (gift of Professor G Margisson, University of 
Manchester, UK). Isogenic HCT116 p53+/+ and HCT116 p53–/– came from Bert Vogelstein.39 Cells 
 - 40 - 
 
were plated into 96-well culture plates at 1 x 103 cells per well and incubated over night at 37 °C in 
a CO2 enriched (5%) atmosphere to enable cells to adhere to the plate. Culture medium was 
removed and replaced with fresh medium containing test compound at concentrations ranging from 
0 (controls) to 250 µM. Following 5 days incubation at 37 °C, cell survival was determined using the 
MTT assay. All TMZ-related compounds were dissolved in DMSO, and the final concentration of 
DMSO in the culture plates was <0.1% (v/v). PaTrin2 was used as an inhibitor of MGMT and cells 




NCI Data Handling 
Standard COMPARE and matrix COMPARE were run using the NCI database Data Build Date: 
2012-04-28. GI50 data were selected and where multiple datasets were available, those averaged 
from the larger number of individual experiments were used. 
 
 
Supporting Information Available: including tabulated IC50 data and statistical analysis for 
Figures 1 and 2; NCI mean graphs and COMPARE results for compounds 2d, 3c–e; HPLC analysis 
of new tetrazines 2, 3. This material is available free of charge via the Internet at http://pubs.acs.org. 
 
Abbreviations Used. ATM, ataxia telangiectasia mutated serine/threonine protein kinase; ATR, 
ataxia telangiectasia and Rad3-related protein; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CCNU, 
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea; CHB, chlorambucil; CP, cisplatin; DTIC, 5-(3,3-
dimethyl-1-triazeno)imidazole-4-carboxamide; FANC, Fanconi’s anemia; GBM, glioblastoma 
multiforme; MEL, melphalan; MGMT, O6-Methylguanine-DNA-methyltransferase; MMR, DNA 
Mismatch repair; 6MP, 6-mercaptopurine; MTIC, 5-(3-methyl-1-triazeno)imidazole-4-
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carboxamide; MTZ, mitozolomide; QSAR, quantitative structure-activity relationship; 6TG, 6-
thioguanione; TMZ, temozolomide. 
 
*To whom correspondence should be addressed. Phone: +44 (0) 1274 234710. 
Email: r.t.wheelhouse@brad.ac.uk.  
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S2 Tables S1 and S2. IC50 Data for Figures 1 and 2. 
S6 Table S3 Statistical Analysis of Chemosensitivity Data. 
S7 Table S4. Listing and Coding of NCI Cell Lines used in the figures. 
Table S5. NSC Codes for 2d, 3c-e. 
S9 Figure S1.  NCI Mean Graphs for TMZ. 
S10 Figure S2.  NCI Mean Graphs for 2d. 
S11 Figure S3.  NCI Mean Graphs for 3c. 
S12 Figure S4.  NCI Mean Graphs for 3d. 
S13 Figure S5.  NCI Mean Graphs for 3e. 
S14 Figure S6.  Superimposed mean graphs of 2d, 3c-e, MTZ and CP. 
S15 Table S6.  COMPARE Results for 2d. 
S16 Table S7.  COMPARE Results for 3c. 
S17 Table S8.  COMPARE Results for 3d. 
S18 Table S9.  COMPARE Results for 3e. 
S20 Figure S6.  Plot of logGI50 vs MGMT. 
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HPLC Analysis of New Imidazotetrazines. 
Elemental Analysis Data for New Imidazotetrazines. 
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Compound P values for Group 1a  P values for Group 2a 
TMZ <0.01 <0.01 
MTZ <0.01 <0.01 
MEL >0.05 >0.05 
CP <0.01 <0.01 
3a >0.05 <0.01 
3b >0.05 <0.01 
3c <0.01 <0.01 
3d <0.01 <0.01 
3e >0.05 <0.01 
3f n/a n/a 
2a <0.01 <0.01 
2b <0.01 <0.01 
2c <0.01 n/a* 
2d >0.05 <0.01 
2e <0.01 <0.05 
2f n/a n/a 
2g <0.01 <0.01 
2h n/a n/a 
2i n/a n/a 
 
Table S3. Statistical Analysis of Chemosensitivity Data 
 
a Student t-test analysis of chemosensitivity data for Group 1 (A2780 vs A2780 + Patrin2) and 
Group 2 (A2780 + Patrin2 vs A2780 Cp70 + Patrin 2). Statistically significant differences were 
defined when P < 0.05; n/a denotes not available due to incomplete data sets or, in the case of 
n/a*, the absence of triplicate experiments (n = 1).   
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Number  Sub-panel Name Cell Name Number  Sub-panel Name Cell Name 
1 Leukemia CCRF-CEM 31 Melanoma M14 
2 Leukemia HL-60(TB) 32 Melanoma SK-MEL-2 
3 Leukemia K-562 33 Melanoma SK-MEL-28 
4 Leukemia MOLT-4 34 Melanoma SK-MEL-5 
5 Leukemia RPMI-8226 35 Melanoma UACC-257 
6 Leukemia SR 36 Melanoma UACC-62 
7 
Non-Small Cell Lung 
Cancer A549/ATCC 37 Ovarian Cancer IGROV1 
8 
Non-Small Cell Lung 
Cancer EKVX 38 Ovarian Cancer OVCAR-3 
9 
Non-Small Cell Lung 
Cancer HOP-62 39 Ovarian Cancer OVCAR-4 
10 
Non-Small Cell Lung 
Cancer HOP-92 40 Ovarian Cancer OVCAR-5 
11 
Non-Small Cell Lung 
Cancer NCI-H226 41 Ovarian Cancer OVCAR-8 
12 
Non-Small Cell Lung 
Cancer NCI-H23 42 Ovarian Cancer SK-OV-3 
13 
Non-Small Cell Lung 
Cancer NCI-H322M 43 Renal Cancer 786-0 
14 
Non-Small Cell Lung 
Cancer NCI-H460 44 Renal Cancer A498 
15 
Non-Small Cell Lung 
Cancer NCI-H522 45 Renal Cancer ACHN 
16 Colon Cancer COLO 205 46 Renal Cancer CAKI-1 
18 Colon Cancer HCT-116 47 Renal Cancer RXF 393 
19 Colon Cancer HCT-15 48 Renal Cancer SN12C 
20 Colon Cancer HT29 49 Renal Cancer TK-10 
21 Colon Cancer KM12 50 Renal Cancer UO-31 
22 Colon Cancer SW-620 51 Prostate Cancer PC-3 
23 CNS Cancer SF-268 52 Prostate Cancer DU-145 
24 CNS Cancer SF-295 53 Breast Cancer MCF7 
25 CNS Cancer SF-539 54 Breast Cancer NCI/ADR-RES 
26 CNS Cancer SNB-19 55 Breast Cancer 
MDA-MB-
231/ATCC 
27 CNS Cancer SNB-75 56 Breast Cancer HS 578T 
28 CNS Cancer U251 57 Breast Cancer MDA-MB-435 
29 Melanoma LOX IMVI 59 Breast Cancer BT-549 
30 Melanoma MALME-3M 60 Breast Cancer T-47D 
   61 Breast Cancer MDA-MB-468 
 
Table S4.  Listing of the NCI60 cell lines assigned arbitrary numbers in Figures 4 and S2-5 
 
 







Table S5.  NCI Code Numbers for compounds 2d, 3c-e. 
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Figures S1-6 
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Table S6. COMPARE Results for 2d using GI50 as seed in the Standard Agents Database 
Rank P Target Vector Identity for Display Target Vector  
1 0.669 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 DTIC 
2 0.615 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 DTIC 
3 0.571 NSC:S755 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 6-mercaptopurine 
4 0.566 NSC:S71851 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 A-TGDR 
5 0.563 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 thioguanine 
6 0.556 NSC:S71261 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 B-TGDR 
7 0.476 NSC:S406021 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 ARA-6-MP 
8 0.467 NSC:S293015 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 flavoneacetic acid ester 
9 0.453 NSC:S320846 Endpt:GI50 ExpId:AVGDATA hiConc:-3.9 batracylin 
10 0.438 NSC:S284751 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 8Cl-cyc-AMP 
11 0.431 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 melphalan 
12 0.425 NSC:S314055 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 SR2555 (nitroimidazole) 
13 0.422 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 mitozolamide 
14 0.414 NSC:S1895 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 guanazole 
15 0.404 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 chlorambucil 
16 0.4 NSC:S3051 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 R-methylformamide 
17 0.393 NSC:S286193 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 tiazofurin 
18 0.387 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 thioguanine 
19 0.374 NSC:S375575 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 cyclopentenylcytosine 
20 0.368 NSC:S261726 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 3-deazaguanine 
21 0.361 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 mitozolamide 
22 0.357 NSC:S95678 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 3HP 
23 0.356 NSC:S344007 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazine alkylator 
24 0.354 NSC:S321803 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 nitroestrone 
25 0.349 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 melphalan 
26 0.344 NSC:S109724 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 iphosphamide 
27 0.343 NSC:S226080 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 rapamycin 
28 0.342 NSC:S253272 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 caracemide 
29 0.342 NSC:S73754 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 fluorodopan 
30 0.34 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 dianhydrogalatitol 
31 0.333 NSC:S32946 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 methyl-GAG 
32 0.332 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 chlorambucil 
33 0.331 NSC:S133100 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 rifamycin SV 
34 0.33 NSC:S286193 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 tiazofurin 
35 0.325 NSC:S192965 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 spirogermanium 
36 0.324 NSC:S366140 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 pyrazoloacridine 
37 0.324 NSC:S344007 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 piperazine alkylator 
38 0.32 NSC:S172112 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 spirohydantoin mustard 
39 0.319 NSC:S375575 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 cyclopentenylcytosine 
40 0.318 NSC:S602668 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 carmethizole 
41 0.316 NSC:S167780 Endpt:GI50 ExpId:AVGDATA hiConc:-3.9 asaley 
42 0.316 NSC:S338720 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 penclomedine 
43 0.315 NSC:S338947 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 clomesone 
44 0.314 NSC:S34462 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 uracil nitrogen mustard 
45 0.311 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 m-AMSA (amsacrine) 
46 0.31 NSC:S77037 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 D-tetrandrine 
47 0.31 NSC:S150014 Endpt:GI50 ExpId:AVGDATA hiConc:-2.5 hydrazine sulfate 
48 0.309 NSC:S139490 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 emofolin sodium 
49 0.308 NSC:S135758 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazinedione 
50 0.307 NSC:S107392 Endpt:GI50 ExpId:AVGDATA hiConc:-2.8 5HP 
1 -0.237 NSC:S3053 Endpt:GI50 ExpId:AVGDATA hiConc:-10.0 actinomycin D 
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Table S7. COMPARE Results for 3c using GI50 as seed in the Standard Agents Database 
Rank P Target Vector Identity for Display Target Vector  
1 0.751 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 DTIC 
2 0.723 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 DTIC 
3 0.56 NSC:S71851 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 A-TGDR 
4 0.543 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 thioguanine 
5 0.524 NSC:S755 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 6-mercaptopurine 
6 0.477 NSC:S71261 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 B-TGDR 
7 0.466 NSC:S406021 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 ARA-6-MP 
8 0.457 NSC:S293015 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 flavoneacetic acid ester 
9 0.433 NSC:S153858 Endpt:GI50 ExpId:AVGDATA hiConc:-8.6 maytansine 
10 0.42 NSC:S192965 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 spirogermanium 
11 0.412 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 chlorambucil 
12 0.409 NSC:S261726 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 3-deazaguanine 
13 0.406 NSC:S253272 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 caracemide 
14 0.402 NSC:S375575 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 cyclopentenylcytosine 
15 0.399 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 melphalan 
16 0.399 NSC:S77037 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 D-tetrandrine 
17 0.395 NSC:S284751 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 8Cl-cyc-AMP 
18 0.394 NSC:S73754 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 fluorodopan 
19 0.374 NSC:S141537 Endpt:GI50 ExpId:AVGDATA hiConc:-7.0 anguidine 
20 0.369 NSC:S303861 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 L-cysteine analogue 
21 0.366 NSC:S344007 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazine alkylator 
22 0.364 NSC:S409962 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 BCNU 
23 0.358 NSC:S73754 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 fluorodopan 
24 0.351 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 m-AMSA (amsacrine) 
25 0.347 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 mitozolamide 
26 0.346 NSC:S102627 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 Yoshi-864 
27 0.346 NSC:S320846 Endpt:GI50 ExpId:AVGDATA hiConc:-3.9 batracylin 
28 0.342 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 mitozolamide 
29 0.341 NSC:S95441 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 methyl-CCNU 
30 0.341 NSC:S1895 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 guanazole 
31 0.339 NSC:S291643 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 pyrimidine-5-glycodialdehyde 
32 0.338 NSC:S361456 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 pyrazine diazohydroxide 
33 0.336 NSC:S95441 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 methyl-CCNU 
34 0.335 NSC:S126771 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 dichloroallyl lawsone 
35 0.333 NSC:S133100 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 rifamycin SV 
36 0.332 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 melphalan 
37 0.33 NSC:S139490 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 emofolin sodium 
38 0.327 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 chlorambucil 
39 0.325 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 dianhydrogalatitol 
40 0.321 NSC:S119875 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 cisplatin 
41 0.319 NSC:S6396 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 thio-tepa 
42 0.318 NSC:S348948 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 cyclodisone 
43 0.316 NSC:S409962 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 BCNU 
44 0.313 NSC:S82151 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 daunorubicin (daunomycin) 
45 0.312 NSC:S150014 Endpt:GI50 ExpId:AVGDATA hiConc:-2.5 hydrazine sulfate 
46 0.312 NSC:S32946 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 methyl-GAG 
47 0.311 NSC:S126849 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 3-deazauridine 
48 0.31 NSC:S286193 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 tiazofurin 
49 0.309 NSC:S34462 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 uracil nitrogen mustard 
50 0.304 NSC:S269148 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 menogaril 
1 -0.261 NSC:S357704 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 cyanomorpholino-ADR 
2 -0.233 NSC:S24559 Endpt:GI50 ExpId:AVGDATA hiConc:-9.0 mitramycin 
3 -0.213 NSC:S118742 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 pentamethylmelamine 
4 -0.209 NSC:S283162 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 trimethyltrimethylolmelamine 
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Table S8. COMPARE Results for 3d using GI50 as seed in the Standard Agents Database 
 
Rank P Target Vector Identity for Display Target Vector  
1 0.717 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 DTIC 
2 0.638 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 DTIC 
3 0.539 NSC:S755 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 6-mercaptopurine 
4 0.512 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 thioguanine 
5 0.504 NSC:S71851 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 A-TGDR 
6 0.469 NSC:S71261 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 B-TGDR 
7 0.396 NSC:S261726 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 3-deazaguanine 
8 0.392 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 mitozolamide 
9 0.38 NSC:S142982 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 hycanthone 
10 0.377 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 mitozolamide 
11 0.373 NSC:S192965 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 spirogermanium 
12 0.362 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 melphalan 
13 0.362 NSC:S320846 Endpt:GI50 ExpId:AVGDATA hiConc:-3.9 batracylin 
14 0.359 NSC:S293015 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 flavoneacetic acid ester 
15 0.358 NSC:S344007 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazine alkylator 
16 0.352 NSC:S119875 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 cisplatin 
17 0.347 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 dianhydrogalatitol 
18 0.338 NSC:S406021 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 ARA-6-MP 
19 0.331 NSC:S153858 Endpt:GI50 ExpId:AVGDATA hiConc:-8.6 maytansine 
20 0.329 NSC:S119875 Endpt:GI50 ExpId:AVGDATA hiConc:-4.3 cisplatin 
21 0.329 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 chlorambucil 
22 0.324 NSC:S409962 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 BCNU 
23 0.319 NSC:S284751 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 8Cl-cyc-AMP 
24 0.316 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 melphalan 
25 0.316 NSC:S375575 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 cyclopentenylcytosine 
26 0.314 NSC:S178248 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 chlorozotocin 
27 0.309 NSC:S141537 Endpt:GI50 ExpId:AVGDATA hiConc:-7.0 anguidine 
28 0.307 NSC:S1895 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 guanazole 
29 0.306 NSC:S82151 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 daunorubicin (daunomycin) 
30 0.305 NSC:S102627 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 Yoshi-864 
31 0.304 NSC:S135758 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazinedione 
32 0.303 NSC:S139490 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 emofolin sodium 
33 0.303 NSC:S314055 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 SR2555 (nitroimidazole) 
34 0.301 NSC:S218321 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 2'-deoxycoformycin 
35 0.3 NSC:S6396 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 thio-tepa 
36 0.295 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 thioguanine 
37 0.293 NSC:S329680 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 hepsulfam 
38 0.292 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 m-AMSA (amsacrine) 
39 0.29 NSC:S95441 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 methyl-CCNU 
40 0.29 NSC:S338947 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 clomesone 
41 0.288 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 chlorambucil 
42 0.288 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 m-AMSA (amsacrine) 
43 0.287 NSC:S9706 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 triethylenemelamine 
44 0.284 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 dianhydrogalatitol 
45 0.282 NSC:S361456 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 pyrazine diazohydroxide 
46 0.28 NSC:S119875 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 cisplatin 
47 0.279 NSC:S126771 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 dichloroallyl lawsone 
48 0.278 NSC:S286193 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 tiazofurin 
49 0.278 NSC:S34462 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 uracil nitrogen mustard 
50 0.278 NSC:S95441 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 methyl-CCNU 
    
1 -0.221 NSC:S357704 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 cyanomorpholino-ADR 
2 -0.215 NSC:S118742 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 pentamethylmelamine 
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Table S9. COMPARE Results for 3e using GI50 as seed in the Standard Agents Database 
Rank P Target Vector Identity for Display Target Vector  
1 0.727 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 DTIC 
2 0.711 NSC:S45388 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 DTIC 
3 0.603 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 m-AMSA (amsacrine) 
4 0.6 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 chlorambucil 
5 0.593 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 melphalan 
6 0.586 NSC:S71851 Endpt:GI50 ExpId:AVGDATA hiConc:-2.3 A-TGDR 
7 0.573 NSC:S752 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 thioguanine 
8 0.551 NSC:S344007 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 piperazine alkylator 
9 0.539 NSC:S102627 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 Yoshi-864 
10 0.532 NSC:S73754 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 fluorodopan 
11 0.532 NSC:S293015 Endpt:GI50 ExpId:AVGDATA hiConc:-3.2 flavoneacetic acid ester 
12 0.528 NSC:S34462 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 uracil nitrogen mustard 
13 0.526 NSC:S3088 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 chlorambucil 
14 0.522 NSC:S253272 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 caracemide 
15 0.515 NSC:S269148 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 menogaril 
16 0.515 NSC:S755 Endpt:GI50 ExpId:AVGDATA hiConc:-3.1 6-mercaptopurine 
17 0.508 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 m-AMSA (amsacrine) 
18 0.506 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.8 dianhydrogalatitol 
19 0.505 NSC:S6396 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 thio-tepa 
20 0.505 NSC:S375575 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 cyclopentenylcytosine 
21 0.502 NSC:S9706 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 triethylenemelamine 
22 0.501 NSC:S73754 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 fluorodopan 
23 0.501 NSC:S141537 Endpt:GI50 ExpId:AVGDATA hiConc:-7.0 anguidine 
24 0.5 NSC:S329680 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 hepsulfam 
25 0.498 NSC:S1895 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 guanazole 
26 0.492 NSC:S51143 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 IMPY 
27 0.491 NSC:S77037 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 D-tetrandrine 
28 0.486 NSC:S71261 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 B-TGDR 
29 0.483 NSC:S32065 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 hydroxyurea 
30 0.481 NSC:S132313 Endpt:GI50 ExpId:AVGDATA hiConc:-3.0 dianhydrogalatitol 
31 0.478 NSC:S95441 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 methyl-CCNU 
32 0.476 NSC:S8806 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 melphalan 
33 0.475 NSC:S284751 Endpt:GI50 ExpId:AVGDATA hiConc:-3.5 8Cl-cyc-AMP 
34 0.47 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 m-AMSA (amsacrine) 
35 0.466 NSC:S303812 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 aphidicolin glycinate 
36 0.466 NSC:S296934 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 teroxirone 
37 0.464 NSC:S25154 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 pipobroman 
38 0.464 NSC:S353451 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 mitozolamide 
39 0.461 NSC:S303861 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 L-cysteine analogue 
40 0.457 NSC:S122819 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 VM-26 (teniposide) 
41 0.457 NSC:S269148 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 menogaril 
42 0.449 NSC:S361456 Endpt:GI50 ExpId:AVGDATA hiConc:-2.9 pyrazine diazohydroxide 
43 0.449 NSC:S762 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 nitrogen mustard 
44 0.449 NSC:S406021 Endpt:GI50 ExpId:AVGDATA hiConc:-2.6 ARA-6-MP 
45 0.447 NSC:S409962 Endpt:GI50 ExpId:AVGDATA hiConc:-3.3 BCNU 
46 0.444 NSC:S348948 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 cyclodisone 
47 0.441 NSC:S82151 Endpt:GI50 ExpId:AVGDATA hiConc:-5.0 daunorubicin (daunomycin) 
48 0.439 NSC:S192965 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 spirogermanium 
49 0.439 NSC:S249992 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 m-AMSA (amsacrine) 
50 0.437 NSC:S750 Endpt:GI50 ExpId:AVGDATA hiConc:-3.6 busulfan 
1 -0.272 NSC:S283162 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0 trimethyltrimethylolmelamine 
2 -0.251 NSC:S118742 Endpt:GI50 ExpId:AVGDATA hiConc:-2.0 pentamethylmelamine 
3 -0.217 NSC:S357704 Endpt:GI50 ExpId:AVGDATA hiConc:-4.6 cyanomorpholino-ADR 
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Next three pages. 
Figures S7–9.  Plots of logGI50 vs. MGMT, MLH1 and MSH6 protein levels in the NCI60 cell lines for 
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HPLC Analysis of New Imidazotetrazines 
 
This method was based on the analysis of TMZ (Kim, H.: Likhari, P.; Parker, D.; Statkevich, P.; 
Marco, A.; Lin, C.-C.; Nomeir, A.A. J. Pharm Biomed. Anal., 2001, 24, 461–468).  A waters 
e2695 instrument fitted with a Waters symmetry C18 column (5 µM, 6.6 × 250 mm) using a 
mobile phase of 0.1% AcOH(aq) and CH3CN (75:25) was employed with a flow rate of 1 mL 
min-1.  The effluent was monitored at 316 nm (λmax of TMZ) and peaks were analysed with 
Empower 3 software. Test compounds were dissolved in DMSO (approx. 5.15 mM in 
imidazotetrazine) and a 10 µL aliquot was diluted with 1 mL of mobile phase before loading onto 
the column. TMZ was used as internal standard and showed a retention time of 3.37 (±0.07) min. 
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Elemental Analysis of Tested Compounds. 
 
 Formula Found Required 
2a C14H15N7O2 C, 53.61; H, 4.84; N, 31.63% C, 53.67; H, 4.83; N, 31.29% 
2b C15H17N7O2·0.25H2O·0.25AcOH C, 53.50; H, 5.15; N, 28.29% C, 53.67; H, 5.38; N, 28.27% 
2c C14H14FN7O2·0.75H2O C, 48.64; H, 4.22; N, 28.16% C, 48.77; H, 4.53; N, 28.43% 
2d C14H14ClN7O2·0.5H2O C, 47.16; H, 3.98; N, 26.94% C, 47.13; H, 4.24; N, 27.48% 
2e C14H14N8O4·0.6AcOH·0.2CHCl3 C, 44.90; H, 3.70; N, 27.08% C, 44.76; H, 4.03; N, 27.38% 
2f C18H20ClN7O4·1/3 H2O C, 49.48; H, 4.70; N, 22.05% C, 49.22; H, 4.73; N, 22.32% 
2g C20H19N13O4·0.25H2O C, 46.87; H, 3.67; N, 35.95% C, 47.11; H, 3.85; N, 35.71% 
2h C15H16N8O4·0.15 H2O C, 47.95; H, 4.20; N, 30.14% C, 48.39; H, 4.33; N, 30.09 % 
2i C15H16N8O5·0.1 H2O C, 46.48; H, 4.19; N, 28.47% C, 46.18; H, 4.19; N, 28.72 % 
    
3a C20H19N13O4 ·H2O·0.8AcOH C, 44.89; H, 3.77; N, 31.41% C, 45.39; H, 4.27; N, 31.86% 
3b C21H21N13O4 ·0.5H2O·2AcOH C, 46.48; H, 4.46; N, 28.14% C, 46.30; H, 4.66; N, 28.07% 
3c C20H18FN13O4·0.35 H2O·0.3AcOH C, 45.40; H, 3.63; N, 33.44 C, 45.89; H, 3.47; N, 34.79 % 
3d C20H18ClN13O4·0.85AcOH C, 44.26; H, 3.69; N, 30.77% C, 44.11; H, 3.65; N, 30.81% 
3e C21H21N13O5 C, 47.16; H, 3.60; N, 33.44% C, 47.10; H, 3.95; N, 34.00% 










1H NMR Spectra (600 MHz, d6-DMSO) of compounds 2a-i, 3a-f 
abundance
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5X












   8.663
   7.679
   7.566
   6.962
   6.948
   6.936
   6.578
   6.564
   6.402
   6.390
   6.378
   4.357
   4.346
   4.335
   3.828
   3.696
   3.685
   3.674












0 0.1 0.2 0.3 0.4 0.5 0.6X













   8.733
   7.770
   7.671
   6.822
   6.807
   6.569
   6.554
   4.456
   4.445
   4.435
   3.778
   3.767
   3.757
   2.862
   2.014












0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6X












   8.784
   8.769
   7.818
   7.797
   7.685
   6.925
   6.921
   6.911
   6.896
   6.889
   6.696
   6.690
   6.682
   6.678
   6.674
   6.667
   4.458
   4.447
   4.437
   3.779
   3.768
   3.757











0 0.1 0.2 0.3 0.4 0.5 0.6 0.7X












   8.790
   7.789
   7.683
   7.094
   7.078
   6.695
   6.679
   4.457
   4.447
   4.436
   3.798
   3.788
   3.777










0 0.1 0.2 0.3X













   8.827
   8.000
   7.985
   7.808
   7.694
   6.819
   6.803
   4.530
   4.520
   4.509
   3.968
   3.958
   3.947











0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1X













   8.795
   7.721
   7.589
   7.306
   7.291
   7.223
   7.208
   4.297
   4.289
   4.279
   3.931
   3.922
   3.914
   3.240
   3.218
   3.194










0 0.1 0.2 0.3X













   8.755
   7.740
   7.609
   7.542
   7.527
   7.465
   7.450
   4.441
   4.431
   4.420
   4.343
   4.333










0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2X











   8.688
   7.705
   7.587
   7.302
   7.132
   7.128
   7.115
   7.077
   7.063
   4.379
   4.369
   4.359
   3.382
   3.372
   3.362
   2.671












0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9X












   8.821
   7.813
   7.694
   7.384
   7.369
   7.190
   7.185
   7.105
   7.100
   7.090
   7.085
   4.444
   4.433
   4.423
   3.698
   3.373
   3.363
   3.353
   3.350
   3.325


























   8.701
   7.692
   7.570
   6.988
   6.974
   6.961
   6.720
   6.705
   6.435
   6.422
   4.355
   4.344
   4.333
   3.713
   3.703
   3.691
   3.236
   3.217











0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1X















   8.781
   7.785
   7.674
   6.833
   6.818
   6.696
   6.682
   4.441
   4.430
   4.419
   3.786
   3.775
   3.764











-0.02 0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16 0.18 0.2 0.22 0.24X












   8.812
   7.806
   7.687
   6.955
   6.940
   6.927
   6.831
   6.825
   6.816
   6.809
   4.443
   4.432
   4.422
   3.794
   3.783










0 0.1 0.2 0.3X












   8.817
   7.802
   7.685
   7.124
   7.108
   6.837
   6.822
   4.447
   4.435
   4.424
   3.806
   3.795










0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1 0.11 0.12 0.13X












   8.662
   7.674
   7.566
   6.644
   6.628
   6.535
   6.520
   4.309
   4.299
   4.287
   3.639
   3.628
   3.616











-0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4X












   8.636
   7.688
   7.586
   7.411
   7.396
   7.078
   7.073
   6.961
   6.956
   6.946
   6.941
   4.234
   4.224
   4.213
   3.584
   3.566
   3.392
   3.382
   3.371
   2.490
   2.400
   2.396
   2.378
   2.262
   1.785
4.15
4.07
3.85
2.86
1.47
0.92
1.04
0.84
– S40–
